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Abstract
Infliximab (IFX) has tremendously enriched the therapy of inflammatory bowel diseases (IBD) and other
immunemediated diseases. Although the efficacy of IFXwas undoubtedly proven during the last decade
numerous publications have also caused various safety concerns. To summarize the immense
information concerning adverse events and safety issues the Austrian Society of Gastroenterology and
Hepatology launched this evidence based consensus on the safe use of IFX which covers the following
topics: infusion reactions and immunogenicity, skin reactions, opportunistic infections (including
tuberculosis), non-opportunistic infections (bacterial and viral), vaccination, neurological complica-
tions, hepatotoxicity, congestive heart failure, haematological side effects, intestinal strictures,
stenosis and bowel obstruction (SSO), concomitant medication, malignancy and lymphoma, IFX in the
elderly and the young, mortality, fertility, pregnancy and breast feeding. To make the vast amount of
informationpracticable for routine application the consensuswas finally condensed into a checklist for a
safe use of IFXwhich consists of two parts: issues to be addressed prior to anti‐TNF therapy and issues to
be addressed during maintenance. Both parts are further divided into obligatory and facultative items.
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One decade ago the introduction of infliximab (IFX), a
monoclonal antibody against TNF-α, has tremendously
enriched the therapy of Crohn's disease (CD). It is highly
effective in various other immune mediated diseases,
mainly rheumatoid arthritis, ankylosing spondylitis, psoriasis,
psoriasis arthritis and ulcerative colitis (UC). The high
prevalence of these diseases and the frequent frustration
by conventional therapies have pioneered the broad appli-
cation of IFX. However, we had to learn early that the other
side of the coin were relevant safety issues. Up to now
numerous publications have brought elucidating knowledge
of how, when and why adverse events can occur. The
profound knowledge of these informations is the basis for
the safe use of IFX and other biological anti-TNF agents which
followed IFX subsequently. This is why the Working Group for
Inflammatory Bowel Diseases (IBD) of the Austrian Society of
Gastroenterology and Hepatology launched this evidence
based consensus on the safe use of anti-TNF therapies. Since
most experience exists for IFX the consensus primarily applies
to this biological agent. However, some of the evidence
concerning safety issues was also adopted from studies using
other anti-TNF agents. A few issues were not specifically
elaborated within this consensus process but discussed in
depth by a recent consensus on opportunistic infections by
the European Crohn's and Colitis Organisation (ECCO) and are
therefore only mentioned shortly within this paper.1
This consensus covers a broad spectrum of safety issues.
To make the vast amount of information practicable for
routine application the consensus statements were con-
densed into a checklist for a safe use of anti-TNF agents
which can be found in Appendix A of this paper. The checklist
consists of two parts: part one focuses on issues to be
addressed prior to anti-TNF therapy, part two is aimed to
monitor safety during maintenance with anti-TNF agents.
Both parts consist of obligatory and facultative items.
2. Infusion reactions and immunogenicity
Consensus statement:
Acute infusion reactions occur in 3–27% of patients
treated with IFX [EL 2, RG B].
The frequency of infusion reactions is lower during
scheduled vs. episodic treatment [EL 1b, RG A].
Routine measurement of antibodies to infliximab (ATIs)
is not recommended [EL 5, RG D].
2.1. Infusion reactions and antibodies to
infliximab (ATI)
IFX is amonoclonal chimeric antibody comprised of 75% human
sequences and 25% murine sequences. Like all exogenousproteins IFX has the potential to induce immunogenicity partly
reflected by the production of so called antibodies to
infliximab (ATIs). The relevance of ATI formation concerning
safety, namely occurrence of infusion reactions, and loss of
efficacy is matter of debate and has most recently been
discussed in a thorough review by Cassinotti and Travis.2
The frequency of ATI development during or after IFX
administration has been reported with a wide variance.
Several reasons are responsible for this variation.2 On the
one hand the frequency of ATI positivitywas found to be higher
with episodic treatment vs. scheduled treatment. In the study
by Baert et al. 61% of patients had developed ATIs by the fifth
episodic infusion, althoughmore than 40% had detectable ATIs
even after the first infusion.3 In contrast under scheduled
treatment, as reported by the ACCENT 1 trial, ATIs were
measurable with a prevalence of 28% in patients after
induction with IFX followed by placebo and in 6–9% of patients
who received scheduled IFX every 8 weeks.4 However, 46% of
patients had an inconclusive ATI status. It needs to be
mentioned that the presence of IFX interferes with the
assessment of ATIs impeding the interpretation of ATI
measurements during maintenance treatment.2,5 Another
factor influencing immunogenicity of IFX is concomitant
immunosuppression. In patients who received episodic treat-
ment those under concomitant immunosuppression developed
ATIs less often and with lower titers as compared to patients
without immunosuppression.3,6,7 In analogy reduction of ATI
formation during concomitant immunosuppression was also
found under scheduled IFX treatment in the ACCENT 1 trial
although not confirmed in another study by Maser et al.4,8
The relevance of ATIs with regard to infusion reactions is
debatable. Two types of infusion reactions have been
described: acute infusion reactions generally occur during
or shortly after the infusion of IFX and typically consist of
fever, chills, nausea, dyspnoea and headaches and may
culminate in anaphylactoid shock. Delayed reactions, char-
acterised by myalgias, arthralgias, fever, rash, pruritus,
facial, hand or lip oedema, dysphagia, urticaria, sore throat
and headache may occur 3–12 days after infusion.
Symptoms of an acute infusion reaction resemble the
symptoms of an anaphylactic reaction. Nevertheless, these
reactions are not true type I hypersensitivity reactions and
are better named anaphylactoid infusion reactions for
several reasons.9–11 First, most of these reactions are usually
not IgE-mediated.12 Second, symptoms of an acute infusion
reaction can be managed by reduced infusion rate. Third,
serum tryptase levels, usually elevated in type I hypersen-
sitivity, were normal in 20 patients after acute infusion
reactions to IFX.9 And fourth, acute infusion reactions have
been described during the first infusion of IFX without
previous exposition to IFX.9,11,13
Infusion reactions are related to the type of treatment
(episodic vs. scheduled) and concomitant immunosuppression.
During episodic treatment the cumulative prevalence was 27%
in the study by Baert et al., with increasing likelihood at each
subsequent infusion.3 Colombel reported 3.8% acute infusion
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infusion reactions occurred during 6% and 4% under scheduled
maintenance with 5 mg/kg and 10 mg/kg, respectively com-
pared to 3% in the placebo group.4 It needs to be stressed that
infusion reactions led to discontinuation of IFX in only 3% of IFX
treated cases. There is only a weak association of ATIs with
occurrence of infusion reactions. ATIs were evaluated in 442
patients of the ACCENT 1 trial and were positive in 64 patients
(14%). Twenty four of 64 ATI positive patients (37%) had an
infusion reaction but so did 42 of 173 ATI negative patients
(24%). The positive predictive value of ATIs for infusion
reactions was only 36%.
Delayed infusion reactions usually occur 3–12 days after
IFX infusion and have a frequency of 1–3%.4,9 They resemble
symptoms of serum-sickness, a type III hypersensitivity
reaction which originally results of tissue deposition of
circulating antigen-antibody complexes.15,16 However, typ-
ical laboratory findings of type III hypersensitivity as
presence of immune complexes and complement activation
have not been demonstrated in delayed reactions to IFX.9
2.2. Management of infusion reactions
Acute infusion reactions are usually easy to manage and
rarely lead to discontinuation of therapy [EL 2, RG B]. In
case of an acute infusion reaction the infusion has to be
stopped and vital signs have to be assessed and
monitored [EL 5, RG D]. The management of an acute
infusion reaction depends on its severity and can
include antihistamines, acetaminophen, steroids,
adrenalin and beta-2-sympathomimetics [EL 5, RG D].
Infusion may be resumed with a low infusion rate after
normalization of vital signs [EL 2b, RG B]. Premedica-
tion should be given prior to subsequent infusions [EL
2b, RG B]. In any case the expected benefit of a
subsequent infusion of IFX has to outweigh the risk of a
subsequent infusion reaction [EL 5, RG D].
Infusion reactions to IFX are most often easily managed and
rarely lead to discontinuation of therapy. Several authors have
developed algorithms for the management of infusion reac-
tions which are very similar.9,11,17,18 In the case of an acute
infusion reaction, the infusion should be stopped (or slowed
down in mild cases) followed by antihistamines (diphenhydra-
mine 25–50 mg) and/or acetaminophen (500–650 mg). After
normalization of vital signs the infusion may be resumed with
an infusion rate of 10 ml/h for 15 minwith stepwise increments
of infusion rates every 15 min. In severe cases steroids are
recommended and in cases of hypotension and wheezing
adrenalin should be given immediately.9,11 In addition oxygen
and beta-2-sympathomimetics may be necessary.
Evidence about the efficacy of premedication before
subsequent infusions in patients with a positive history of an
infusion reaction is scarce. Jacobstein et al. reported
subsequent infusion reactions in 20% of patients with
premedication (antihistamines, antipyretics, steroids) and
50% in patients without.19 Nevertheless, the numbers in this
study are very low which is also why there was no statistical
significance and detailed information concerning premedica-tion is also missing. Colombel reported re-treatment of 11
patients after previous infusion reactions ofwhom8developed
subsequent reactions despite methylprednisolone, diphenhy-
dramin and paracetamol.14 Cheifetz et al. reported that
subsequent infusions were successfully administered in all
patients with previous mild to moderate infusion reactions
following a standardised protocol of premedication.9 Also
after severe reaction retreatment was possible without
problems in 2 of 4 patients. Most experts advocate a
premedication at least with diphenhydramin and paracetamol
and start infusion at a very low rate (10 ml/h) with subsequent
increments every 15 min.9,11,17,18 Some authors additionally
recommend a premedication with steroids (up to 1 mg/kg of
prednisolone) at least if the previous infusion reaction was
severe. Steroids have a delayed onset of action of at least
15 min which has to be borne in mind when using them in this
setting. Duburque et al. reported on the successful induction
of tolerance to IFX in patients with CD and prior severe infusion
reactions: Each infusion of IFX (5 mg/kg) was divided into 11
escalating 15 min increments over a 3-h time period.10 In any
case the expected benefit of a subsequent infusion of IFX has to
outweigh the risk of a subsequent infusion reaction and should
be considered in the light of the possibility of a switch to an
alternative anti-TNF agent.
Delayed reactions often resolvewithout treatment although
some authors suggest antihistamines and/or paraceta-
mol.9,11,18 Steroidsmaybe added if treatment is unsatisfactory.
2.3. Autoantibodies and drug induced lupus
Consensus statement:
Treatment with IFX may be associated with autoim-
mune phenomena and the development of antinuclear
antibodies (ANA) and of antibodies to double-stranded
DNA. [EL 3, RG C]
Monitoring of autoantibodies is not currently considered
necessary as associations with treatment response, toxic-
ity or autoimmune events are controversial [EL 3 RG C].
Cases of true systemic lupus erythematosus or IFX
related eruption in the context of autoimmunity are
rare. All cases reported were reversible upon discon-
tinuation of treatment. (EL 4, RG D).
In 35 CD patients with IFX treatment induction of ANA and
anti-dsDNA autoantibodies was observed in 53% and 35% of
infliximab-treated patients with CD, respectively.20 A single
patient who developed ANA and anti-dsDNA autoantibodies
showed clinical features consistent with drug-induced lupus.
According to the Mayo clinic's experience in 500 CD patients 3
patients developed drug-induced lupus.14 A literature search
for the isolated single-case reports of drug-induced lupus
erythematodes (DILE) due to anti-TNF-α agents resulted in
33 cases, which were distributed among IFX (n=21),
etanercept (n=10) and adalimumab (n=2). The authors
delineate, that TNF-α DILE has significant clinical and
laboratory manifestations which distinguish it from DILE
due to drugs other than anti-TNF agents and may be difficult
to diagnose in patients treated for autoimmune diseases.21
Another paper reviewed 105 cases of lupus-like syndrome
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occurred under IFX and 90% of cases occurred in patients with
rheumatoid arthritis suggesting a subclinical pre-existing
overlap between rheumatoid arthritis and lupus.
3. Skin reactions
The spectrum of adverse reactions with dermatological
manifestations caused by TNF alpha antagonists subsumed
under the term “drug eruption” are strongly dependent on the
source of information and the medical discipline (Gastroen-
terology, Rheumatology, Dermatology) the authors belong to.
The different approach explains why it is not easy to compare
the frequencies of cutaneous side effects caused by IFX
reported in different publications. In addition the clinical
diagnosis is only exceptionally verified by histopathology.
3.1. General frequency of skin reactions
Consensus: Skin symptoms are frequent adverse reac-
tions induced by IFX. [EL 1b, RG B].
Recently Fidder et al. presented data of a large single-
centre cohort on the long-term safety of infliximab for the
therapy of IBD.23 In 150 of 734 patients (20%) of the IFX group
skin eruptions developed. Sixty four patients were referred
to the dermatologist due to severity of symptoms. Of these
61% were diagnosed with psoriatiform lesions. Also eczema
was frequently diagnosed. The most frequent symptoms
were itching and pain. Fifteen percent of patients underwent
biopsy revealing three types of lesions: eczema with
spongiotic dermatitis; psoriasis with psoriasiform acanthosis;
and parakeratosis, dilated capillaries and subcorneal pustule
formation. Most cases responded to topical steroids. IFX had
to be discontinued in only two patients.
3.2. Exacerbation orde novodevelopment of psoriasis
Consensus: Infliximab may induce first manifestation of
psoriasis or exacerbation of pre-existing psoriasis [EL 4;
RG C].
In mild and moderate cases IFX may be continued or
switched to an alternative anti-TNF agent in addition to
topical and/or systemic anti-psoriatic therapy [EL4;RGC].
If this strategy fails discontinuation of TNF alpha
antagonist therapy is inevitable [EL 4, RG C].
In 2004 the first reports were published on an interesting
because paradoxical side effect of IFX.24,25 Although anti-
TNF alpha antagonists are used successfully for the treat-
ment of “high-need” plaque psoriasis and psoriatic arthritis
some patients who receive anti-TNF therapy for various
indications including IBD may develop de novo psoriatic skin
lesions 1–14 months after initiation.26–28 The prevalence
ranges between 0.6% and 5.3%.29 Psoriasis may be induced byIFX, etanercept and adalimumab although half of the 120
cases reported received IFX.30 Pustular psoriasis — frequent-
ly on palms and soles — is the most common type of anti-TNF
induced psoriasis. Anti-TNF induced psoriasis does not
necessarily require discontinuation of anti-TNF therapy.
With (mostly topical) anti-psoriatic therapy complete remis-
sion was reported in 45% of patients stopping TNF antagonists
and 47% in patients continuing TNF antagonists.30 Collemar
et al. also reviewed 104 cases of psoriasis induced by
different anti-TNF agents from the literature.31 Thirty
percent of patients had complete resolution and 31% had
partial resolution under continued anti-TNF therapy. Further
5% had resolution after change to another anti-TNF com-
pound. Unfortunately it was not specified which substance
was the primary or the subsequent anti-TNF agent, respec-
tively. Seventeen percent were discontinued all of which had
complete (13%) or partial (4%) resolution. Thus, the majority
of patients in these two analyses (with some redundancy)
could be kept on anti-TNF therapy. In contrast Rahier et al.
reported that switching the anti-TNF antagonist led to
recurrence of psoriasis in 16/16 patients.32 The most recent
review, compiled of 127 cases (55% under IFX), came to a
different result, too:29 in this paper resolution after switch
to another anti-TNF agent led to resolution in only 15%,
topical steroids led to improvement in 27% and stopping anti-
TNF therapy plus systemic therapy led to resolution in 64%.
3.3. Malignancies of the skin
Consensus:
The risk of malignancies of the skin is increased under
IFX treatment. [EL3 RG C].
Patients with additional risks for the development of
skin malignancies should be referred for skin examina-
tions at baseline and followed up regularly [EL 5RG D].
In patients with a history of malignant melanoma the
decision for IFX therapy should be made in conjunction
with the dermato-oncologist and the patients should
remain under close dermatologic observation [EL5, RGD].
IFX slightly increases the frequency of malignant skin
tumours, both malignant melanoma (MM) and non-melanoma
skin cancer (NMSC) although true incidences are possibly
confounded by concomitant use of phototherapy and other
immunosuppressants.33–35 In a large observational study
among patients with rheumatoid arthritis use of anti-TNF
agentswas associatedwith an increased risk ofMM (OR2.3) and
NMSC (OR 1.5).36 In IBD Fidder et al. reported 8 NMSC besides
15 “malignancies” (not specified further) per 3775 patient-
years in patients receiving IFX and 5 NMSC plus 37 “malignan-
cies” per 6704 patient-years in patients not receiving IFX.23
There was no significant difference in the total number of
“malignancies” in the two groups whereas the number of NMSC
seems to be higher among patients with IFX therapy.
Whether IFX has to be stopped after the diagnosis of
cutaneous malignancy or if it is contraindicated in patients
with a positive history of skin malignancies has not been
evaluated so far. Therefore no clear recommendation can be
given in this respect. In a recent review Kerblesky and
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to be withdrawn.35 The decision has to be made in con-
junction with the treating dermatologist and the informed
patient. Important factors include type and prognosis of the
skin malignancy, complete excision, appropriate manage-
ment and follow up, as well as a fortunate risk/benefit ratio.
A history of excised basalioma is usually no exclusion criterion
in clinical trials and thus far should not withhold a routine
patient from an effective therapy.
To prevent the development of serious malignant com-
plications of the skin patients with additional risk factors for
the development of skin malignancies (high cumulative UV
exposure, melanoma precursor lesions, history of photo-
chemotherapy, and history of other immunosuppressive
therapies) or with unclear dermatologic conditions should
see a dermatologist before starting anti-TNF therapy.
3.4. Infliximab-induced vasculitis
Drug-induced hypersensitivity reactions may present with a
wide spectrum of clinical pictures including cutaneous
vasculitis.37 The precise rate of these adverse skin reactions
is not known at present because in most reports the eruptions
are not specified. After marketing, the number of reports on
cases of anti-TNF antagonist induced vasculitis is increas-
ing.38–42 In a recent review 118 cases have been described, of
which 51 occurred under infliximab. Over 90% of these cases
occurred in patients with rheumatoid arthritis which is by
itself associated with vasculitis.43 Some cases present with
typical leucocytoklastic vasculitis, but also urticaria vascu-
litis and lymphocytic vasculitis have been described. The
typical clinical symptoms are painful hemorrhagic nodules
which predominantly develop on the lower limbs and appear
intermittently. A nationwide survey in France identified 29
cases of vasculitis in patients taking TNF-α antagonists.
Antinuclear factor (ANF) was present in 22 patients,
hypocomplementemia in 6, and antineutrophil cytoplasmic
antibody in 5. However, the relative contributions of TNF-
alpha antagonist therapy and of the underlying disease to the
development of vasculitis are undetermined.44 Systemic
glucocorticosteroid therapy is the treatment of choice.39
According to the classification by Pichler lymphocytic
vasculitis induced by TNF alpha antagonists would be a
type γ reaction (immune/cytokine imbalance syndrome) and
not a true type III hypersensitivity reaction.45 In patients
with severe hypersensitivity reactions and hypersensitivity
reactions which regularly relapse and worsen with every new
administration anti-TNF therapy should be discontinued.
3.5. Steven Johnson syndrome and toxic
epidermal necrolysis
Although rarely, IFX is also reported to induce bullous drug
eruptions such as Steven–Johnson syndrome (SJS) and toxic
epidermal necrolysis (TEN).13,46,47 SJS presents with an
eruption of wide spread atypical target-like lesions whereas
typical target lesions are rare. The reaction also involves the
mucous membranes (conjunctivae, mucous membrane of
mouth and genitals). TEN is a rare but potentially life-
threatening complication of IFX therapy. One to two days
after start of therapy extended light redmacules appearwhichmay reach erythrodermic dimensions. Finally flabby blisters
develop and there is hair loss and loss of nails. Involvement of
inner organs (e.g. necrotizing tracheitis, bronchiolitis, eso-
phagitis, glomerulonephritis) is possible. Paradoxically, the
pathogeneticmechanism of both, SJS and TEN is characterized
by extensive apoptosis of keratinocytes via massive release of
TNF-α from cytotoxic T-lymphocytes.37 This is the reason why
the number of reports on the successful use of anti-TNF
therapy for drug-induced SJS and TEN is increasing.48 Thus, SJS
and TEN may be both induced by IFX and treated with IFX
(unless induced by IFX). If new cutaneous eruptions with
mucosal involvement, suggestive for SJS or TEN, occur in the
context of IFX therapy, IFX has to be stopped and the patient
has to be immediately referred for inpatient management.
3.6. Other cutaneous lesions
Infliximab induced drug eruptions show a broad spectrum of
clinical manifestations.49
Among these lichenoid exanthems are the most frequently
reported.50 The interval between start of TNF alpha antagonist
therapy and the onset of this adverse reaction is severalmonths.
Polygonal-shaped, red blue, confluent papules are the charac-
teristically lesions of this type of delayed type hypersensitivity
reactions. The exanthema is both clinically and histopatholog-
ically difficult to distinguish from genuine lichen planus.
4. Opportunistic infections
TNF-α antagonists suppress the activity of tumor necrosis
factor (TNF)-α, a proinflammatory cytokine that plays an
essential role in the human immune response to infection.
Not unexpectedly, various infections with opportunistic
pathogens including Mycobacterium tuberculosis, Listeria
spp., Histoplasma capsulatum, Coccidioides immitis, Pneu-
mocystis, and Cytomegalovirus have been observed in
association with the use of these anti-TNF agents.
4.1. Tuberculosis
Consensus statement:
The risk of clinical tuberculosis is increased in patients
receiving treatment with IFX. Application of official
recommendations to prevent reactivation of latent tuber-
culosis infection reduces the incidence of active tubercu-
lous disease associated with IFX therapy. [EL 2b RG B]
Any patient who is a candidate for IFX therapy must be
screened for infection withMycobacterium tuberculosis
according to the local guidelines. [EL1b, RG A]
Chemoprophylaxis for latent tuberculosis infection
should be started before initiation of IFX therapy
[EL4, RG D].
During IFX treatment regular monitoring for symptoms
suggestive of clinical tuberculosis is recommended
[EL4, RG D].
Of foremost concern is reactivation of latent tuberculosis to
tuberculosis disease, because tuberculosis has implications on
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to an estimate of the WHO about one third of the word
population is infected with tuberculosis.51 The risk of active
tuberculosis after latent infection is approximately 10% within
a lifetime, but is increased in individuals whose immune
systems are compromised by disease or drugs.52,53 The first
case of tuberculosis during treatment with IFX was observed in
1999. Through May 2001, 70 patients who developed active
tuberculosis in association with IFX use had been reported.54
The frequency of tuberculosis in randomized clinical trials
with TNF-blockers was low. In 16 randomized clinical studies
on IFX, 3 cases of tuberculosis were reported in 3882 patients
receiving IFX, and none were reported in 2430 receiving
placebo or comparator control.55Westhovens et al. performed
a placebo-controlled trial to assess the safety profile of IFX
during one year in 1084 patients with rheumatoid arthritis.56
Seven patients developed active tuberculous disease which
occurred more frequently at a higher dose (N3 mg/kg). All
seven patients had baseline negative tuberculin skin tests
(TST) and the majority had extrapulmonary disease.
There are detailed case reports of more than 40 patients
who developed tuberculosis during or after anti-TNF therapy
e.g..57–68 Most of these patients had received IFX for therapy
of rheumatoid arthritis but tuberculosis was also reported
under etanercept69,70 and adalimumab.71–73 Based on phar-
macovigilancedata the incidenceof tuberculosis under IFXwas
estimated between 144 and 173 cases per 100,000 patients —
several times higher than the background rate in most
European countries.74–76 In these pharmacovigilance studies
the incidence of tuberculosis may be underestimated since
reporting is voluntary. Databases established in the USA and in
Europe allow long term follow-up and assess the safety of
biologic response modifiers noting relevant adverse events
during treatment. In the USA, Wolfe et al. evaluated 10,782
rheumatoid arthritis patients in 1998–1999 prior to the
widespread use of IFX, and 6460 IFX-treated patients in
2000–2002.77 Prior to the use of IFX the rate of tuberculosis
was 6.2 cases per 100,000 patient years, similar to the general
USpopulation. In contrast, in IFX exposed patients the ratewas
52.5 per 100,000 patients years. An even higher incidence was
estimated for Canada.78 A Spanish multicenter active-surveil-
lance report estimated an incidence of tuberculosis associated
with IFX of 1503 cases per 100,000 patients with rheumatoid
arthritis as compared to 95 per 100,000 patients without IFX
exposure and 21 cases per 100,000 inhabitants of the Spanish
background population.79,80 A Swedish population-based
registry calculated a 4-fold increased risk of tuberculosis for
the use of IFX.81 Tuberculosis was diagnosed at a medium
interval of 12 weeks after the beginning of anti-TNF-a therapy
and occurred in the majority of patients within three cycles of
treatment,more than half of the patients had extrapulmonary
disease and 24% had disseminated disease.54 Similar results
were found in a British registry82 and in a Japanese
postmarketing surveillance study which additionally identified
the lack of chemoprophylaxis as risk factor tuberculosis.83
Although not studied in detail, the risk for active TB might
be increased in patients with IBD that have not been treated
with anti-TNF drugs.84 Similarly, in patients with rheumatoid
arthritis without therapeutic TNF blockade, the incidence of
TBwas higher than in a control population inmost (but not all)
studies (see above). IFX increases the background risk of
tuberculosis by approximately fivefold in both Crohn's diseaseand rheumatoid arthritis.85,86 A comparison of AERS data
among patients from the US found a significantly higher rate
of reported cases with active tuberculosis after administra-
tion of IFX than after etanercept. The risk of granulomatous
infection was 3,3-fold greater among patients who received
IFX than in patients who received etanercept, and the
clustering of reports shortly after initiation of IFX treatment
likely represents re-activation of latent infection.76 Overall,
there exist no prospective data that compare rates of
tuberculosis between the various anti-TNF drugs. Despite
the fact that theremay be differences, tuberculosis should be
considered a risk with all of these agents.
4.1.1. Practical aspects
Before anti-TNF therapy is initiated, patients need to be
screened for latent tuberculosis (LTBI).17,86,87 Of foremost
importance is a detailed medical history that includes
tuberculosis risk factors such as birth or extended residence
in a region of high tuberculosis prevalence, previous tubercu-
losis or tuberculosis treatment, or a history of any of the
following: residence in a congregate setting (e.g. prison,
homeless shelter, or long-term care facility), substance abuse,
health-care employment in centers that treat tuberculosis
patients, a positive TST result, and chest radiographic findings
consistent with previous tuberculosis.88,89 Patients should
then be screened with a TST, which relies on a delayed type
hypersensitivity response to intradermal inoculation of tuber-
culin purified protein derivate. Unfortunately, the reliability
of the TST is limited. The positive predictive value of the TST in
populations at low risk of M. tuberculosis infection is less than
50%,90 as false positive results may occur in people infected
with non-tuberculous mycobacteria, and in recipients of the
Bacille Calmette–Guérin (BCG) vaccine, if the vaccine was
given after the first year of life.75,91 In patients withweakened
cellular immunity the TST is more likely to yield false-negative
results — a limitation that has particular importance when
treating patients with IBD who are frequently immunosup-
pressed due to medical therapy other than infliximab. In one
study, the prevalence of anergy among IBD patients has been
reported to amount 71%.90 In such patients the TST may fail to
detect LTBI, and accordingly, several cases of active tubercu-
losis occurred in patients who had negative TST results before
initiation of anti-TNF therapy.56 Thus, a negative test result
should be considered suspect. The performance of a booster
TST diagnoses 8–14% additional cases of LTBI in patients with
IBD and rheuma, and may thus be considered 1–8 weeks after
the first negative TST according to national guidelines.92–95
Two new interferon γ release assays (IGRA) target unique
proteins that are highly specific of Mycobacterium tuberculo-
sis but absent from BCG vaccine. These tests are commercially
available (QuantiFERRON-TB and ELISPOT) and have been
shown to be more sensitive and specific than standard TST in
immunocompetent and immunocompromised patients. If
available, IGRA can complement the TST and have a preferred
role in BCG vaccinated patients.96–103
If clinical suspicion for past exposure to tuberculosis is high,
consideration should be given to prophylactic antimicrobial
therapy despite negative TST. Chest radiography is widely used
to screen patients for tuberculosis before anti-TNF therapy.
Chest radiographs are useful in screening for active tubercular
disease, but are not useful in screening for LTBI, as
most latently infected individuals have normal chest
228 W. Miehsler et al.radiographs.88,89 Furthermore, granulomatous lesions seen on
chest radiography are nonspecific for LTBI and can result froma
variety of infectious and noninfectious diseases. If chest
radiography is abnormal, or patients have symptoms raising a
suspicion of tuberculosis, they should be thoroughly investi-
gated to exclude active disease. Before exclusion of active
tuberculosis, anti-TNF therapy must be withheld. There is
evidence to suggest that after implementation of screening
and treatment of latent tuberculosis, the incidence of active
tuberculosis disease following anti-TNF therapy decreased. In a
survey including 6460 IFX-treated RA patients in the US four
cases of tuberculosis were found and none of them had
received tuberculosis screening before initiation of anti-TNF
therapy; among patients who received TST before IFX therapy
(about 50% of the cohort), none was diagnosed with active
tuberculosis disease.77 In addition, Carmona et al. found that
after the implementation of official recommendations regard-
ing the management of active tuberculosis in RA patients
receiving anti-TNF therapy, rates of active tuberculosis
dropped by 83% and reached the rate of RA patients not
treated with TNF-blockers.104
4.1.2. Treatment of LTBI
Before treatment of LTBI is initiated, active tubercular
disease must be excluded.
In patients whose clinical or epidemiological circum-
stances suggest a probability of LTBI, prophylactic antimi-
crobial therapy despite a negative TST should be considered.
Patients diagnosed as having LTBI should receive preventive
treatment before TNF-blocking agents are started. Most
commonly, treatment with daily isoniazide for 6–9 months is
recommended, although therapy may vary according to
geographic area or the patient's epidemiological background.
For patients who undergo anti-LTBI treatment, the optimal
time for commencing TNF-antagonist therapy is undeter-
mined. A conservative approach is to postpone therapy with
TNF antagonists until treatment for LTBI is completed; in
severe cases anti-TNF therapy may be instituted earlier (e.g.
3 weeks after starting chemoprophylaxis), provided the
patient is compliant in taking the prescribed anti-tuberculo-
sis medication. It is important to recognize that no
chemoprophylaxis regimen is wholly effective; protective
effects of 60% have been reported for therapy with isoniazide
for 6 months,105 and of 50% for rifampicin plus isoniazid for
3 months.85 Gastroenterologists treating IBD patients with
TNF-blockers are advised to closely collaborate with a
specialist tuberculosis physician. Considering that LTBI may
remain undetected, and that treatment for LTBI may fail, all
patients on anti-TNF therapy must be monitored carefully for
symptoms suggestive of clinical tuberculosis.4.2. Listeriosis
Consensus statement:
Patients treated with IFX are at increased risk of
infections with Listeria monocytogenes [EL 4, RG C].
Before initiation of IFX patients should be educated to
avoid potentially infected foods such as unpasteurized
milk products and undercooked meat [EL 5, RG D].Listeria monocytogenes is a gram-positive intracellular
bacterium that is supposed to enter the body by ingestion of
certain foods including soft cheeses, unpasteurized milk,
undercooked meets and hotdogs. Infection most commonly
occurs among newborns, pregnant women, and hosts with
compromised immunity and cellular deficits. Usually L.
monocytogenes causes meningoencephalitis and/or septice-
mia. Case reports and postlicensure surveillance indicate
that L. monocytogenes infection is linked to the treatment
with IFX.106–111 Slifman reviewed the AERS passive monitor-
ing system and identified 15 cases of L. monocytogenes
infection.106 Most of the patients were older than 60 years,
and received concurrent immunosuppressant drugs during
anti-TNF therapy; six of the 15 patients died. If patients
treated with anti-TNF drugs present with meningitis or other
neurological symptoms they should receive full attention and
be investigated intensively (including lumbar puncture).
Diagnosis relies on appropriate microbiological culture. In
case of infection anti-TNF drugs should be stopped.
4.3. Histoplasmosis
Histoplasma capsulatum is transmitted by inhalation of
mycelial fragments and microconidia of the organism after
disturbance of contaminated soil. As of September 2002
there were 37 cases of histoplasmosis reported in the AERS
data among patients receiving IFX and three with etaner-
cept.76 Ten of these cases were evaluated in detail; all
patients lived in areas where histoplasmosis is endemic and
received concomitant immunosuppressive medications in
addition to the anti-TNF therapy.112 Three additional case
reports of histoplasmosis associated with IFX therapy were
published.113–115 The rate of histoplasmosis in US patients
following treatment with IFX or etanercept was estimated
to be approximately 19:100,000 and 3:100,000, respec-
tively.76 Histoplasmosis also occurred after treatment with
adalimumab.116
4.4. Other fungal infections
Consensus statement:
During IFX therapy reactivation of granulomatous fungal
infections may occur [EL 4, RG C].
Although the incidence of opportunistic fungal infections
is very low, physicians should be vigilant while using IFX,
especially in areas of high disease prevalence [EL 5, RG
D].
Spontaneous cases of other fungal infections in associa-
tion with IFX therapy have been reported in the literature
including Candida spp., Aspergillus spp., Cryptococcus
neoformans, Cryptococcus immitis, Sporothrix schenckii,
Coccidoidomycosis, and Nocardia spp.83,117–122
4.5. Pneumocystis jiroveci
Several reports document a temporal relationship between
anti-TNF-therapy and infection with Pneumocystis jiroveci
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as a protozoan for many years.83,123–127 The risk of Pneu-
mocystis pneumonia appears to be relatively high in Japan,
where in a population of 5000 patients with RA the incidence
was 0.4%.83 The median length of time from the first
infliximab infusion to the development of pneumonia was
8.5 weeks. Diagnosis is based on the identification of P.
jiroveci from bronchopulmonary secretions and on polymer-
ase chain reaction test for the organism. Most patients
respond to appropriate treatment, but mortality rate may be
more than 25%.
Although the level of evidence is low all 22 participants of
the ECCO consensus on opportunistic infections agreed to
commence chemoprophylaxis with cotrimoxazole in patients
under triple immunosuppression including IFX or cyclosporine
given the high mortality of P. jiroveci infection [EL 4, RG D].1
It is important to stress that concomitant immunosuppression
to IFX should be restricted to the shortest time possible.
5. Non-opportunistic infections
Consensus statement:
The risk for infections in general and the risk of serious
infections (need for hospitalisation, parenteral antibi-
otic treatment) is increased under immunomodulatory
therapy including IFX [EL1a, RG B].
Patients should be informed about the risk of infections
and instructed to consult a physician or general
practitioner when signs of infection occur [EL 5, RG D].
Data concerning the rate of non-opportunistic infections
in association with an anti-TNFα agent derive from studies
and applications of these substances in patients with
rheumatoid arthritis (RA), inflammatory bowel diseases
(IBD), mainly Crohn's disease (CD), and patients with
psoriasis. Most data are available from RA patients.
However, the validity of an extrapolation of data from
patients with RA to patients with other diseases like IBD may
be limited for several reasons: 1) RA is by itself associated
with an increased risk of infections such as pneumonia or
joint infections.128 2) Patients with rheumatoid arthritis are
on average older than patients with IBD. 3) The standard
dose of IFX is almost twice as high in IBD than in RA. 4) Three
different anti-TNF agents are licensed for the use in RA for
several years now, whereas the main experience for the use
in IBD comes from IFX . It cannot be excluded that there are
some differences between IFX, adalimumab and etanercept
concerning safety issues with regard to infections.
5.1. Bacterial infections
Data concerning the risk of bacterial non-opportunistic
infections under anti-TNF therapy are conflicting: A meta-
analysis of 9 randomised controlled trials of IFX or adalimu-
mab in RA including 3493 patients allocated to anti-TNF
agents and 1512 patients allocated to placebo showed an
increased rate of infections under anti-TNF agents (OR 2.0,
95%CI 1.3–3.1).34 In IBD another meta-analysis of 21randomised controlled trials including 5356 patients with
Crohn's disease did not reveal an increased risk for severe
infections.129 Given that patients included in RCT are usually
informed about the risk of and signs for infections and are
under thorough observation of specialised physicians with
high awareness for infection such data do not reflect real
life.
Other data sources draw another picture: Data from the
RABBIT registry, which included 346 RA patients under IFX
and 601 controls, showed that overall the rate of infections
was significantly increased under IFX (21% vs. 6%,
Pb0.0001).130 These results were not supported by British
data from the BSRBR which did not show an increased risk of
serious infections in RA under anti-TNF agents compared to
DMARDs.82 However, the rate of respiratory tract infections,
as most frequent site of infection, was considerable high in
the DMARD group of the BSRBR compared to other studies
which carries the risk of a beta-error. Additionally, the
comparability of the anti-TNF group and the DMARD group
may be biased by the possibility that patients with a high risk
for infections may have been more likely to be withheld from
an anti-TNF therapy. Interestingly the rate of intracellular
bacterial infections and skin and soft tissue infections was
increased in the BSRBR registry. Concerning the risk of
infection in patients with IBD under anti-TNF therapy several
studies have been published. In the study by Ljung et al. 217
patients with IBD received a median of 2.6 infusions.131 In 41
patients severe adverse events were reported including 11
(5%) infections. Three patients died from an infectious
complication. Another series of 500 IBD patients treated with
IFX reported 41 infections (8.2%) at least possibly related to
IFX.14 Fifteen patients had serious infections including fatal
sepsis (n=2) and pneumonia (n=8), fatal in 2 cases. The
largest registry concerning serious infections in IBD is the
TREAT registry including 3179 CD patients who received IFX
and 3111 patients receiving other therapies.132 Without
adjustment for other factors the risk for serious infections
was significantly higher in IFX treated patients (1.37 vs. 0,6
per 100 patient years; RR 2.15; 95%CI 1.44–3.21; Pb0.001)
and these infections mainly occurred within 3 months of IFX
exposure. However, when adjusting for confounders (race,
moderate-severe CD, disease duration, prednisolone, use of
narcotic analgesics) the effect of IFX on serious infections
was not significant (OR 0.99; 95%CI 0.64–1.54; P=0.97). The
study by Lees et al., including 202 patients with IBD with 620
patient years of follow up reported infectious events in 21%
of patients and serious infections in 11%.133 When compared
to other immunomodulatory agents population based data of
10.622 IBD-patients from British Columbia showed that the
risk of serious bacterial infections was not higher under
infliximab.134
5.1.1. Respiratory tract infections
There are conflicting data whether the risk for pneumonia
and other lower respiratory tract infections is increased
under anti-TNF therapy. Most of the differences are perhaps
due to methodological issues which concern the compara-
bility of IFX groups and control groups in registries as well as
the case ascertainment.135 As reported by the RABBIT
registry the rate of serious and non-serious upper respiratory
tract infections, pneumonia and other lower respiratory
tract infections excluding tuberculosis was increased under
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incidence of pneumonia was 2.4–4.7 times higher under IFX
as compared to patients under DMARDs. These data were not
confirmed by others.82,136
We have to consider an increased risk of lower respiratory
tract infections under IFX. Since the majority of community
acquired respiratory tract infections are caused by pneu-
mococci, vaccination against pneumococci is recommended
(see below). The French RATIO registry following 486
patients under anti-TNF treatment reported an increased
risk of pneumonia due to Legionella species.137 There are no
data on diphtheria under anti-TNF therapy.
5.1.2. Urinary tract infections
In IBD a urinary tract infection has been reported in 1 of 500 IFX
treatedpatients.14 Also inRA the risk for urinary tract infections
was not significantly increased under anti-TNF treatment (IRR
1.7, 95%CI 0.3–9.0).82 The RABBIT registry reported no
increased risk of urinary sepsis under anti-TNF therapy.130
5.1.3. Skin and soft tissue infections
Lethal sepsis due to skin and soft tissue infections in
association with IFX therapy has been reported.14,138 The
RABBIT registry showed that RA patients under IFX experi-
enced more episodes of erysipelas, furuncle, abscess and
paronychia than patients under DMARDs (7.7 vs. 2.6 per 100
patient years, P=0.0017).130 Also data from the BSRBR
showed an incidence risk ratio of 4.3 (95%CI 1,1–17,2)
concerning skin and soft tissue infections under anti-TNFα
agents. In IBD 6 of 500 patients treated with IFX experienced
a skin or soft tissue infection.14 There are no data on
scarlatina under anti-TNF therapy.
5.1.4. Abscess
Consensus statement:
Abscess formation can occur under a therapy with IFX
for perianal fistulising CD. The exclusion of abscesses by
imaging procedures and sanitation of abscesses by
drainage or seton placement must precede the therapy
with IFX [EL 2b, RG B].
Fistulas occur in approximately one third of patients with
CD and can lead to abscess formation somewhere along the
fistulous tract. The efficacy of IFX concerning the healing of
fistulas is proven for short term as well as for mainte-
nance.139,140 Patients with clinical signs of abscesses at
baseline were excluded from both mentioned studies.
Development of abscesses was reported in 11% under IFX
and 3% under placebo in the study by Present et al. In
patients who all received an induction therapy with IFX for
fistulising CD development of abscesses was reported in 12%
under IFX maintenance and 17% under Placebo maintenance.
These abscesses could occur in the induction phase as well as
in the early or late maintenance phase and there was no
difference between both groups.141 It is known that
abscesses occur in a large number of patients with perianal
fistulas and can be detected by imaging procedures or
surgical exploration under anaesthesia. It has been shown
that surgical sanitation of abscesses by incision or setonplacement prior to IFX improves the outcome of these
patients and may avoid abscess formation during IFX
treatment.142–144
5.1.5. Clostridium difficile
The literature concerning C. difficile was reviewed in depth
for the ECCO consensus on opportunistic infections.1 The
statements (OI 7O–OI 7 S) mainly concluded that IBD is a risk
factor for C. difficile infection, while patients with colonic
involvement are particularly susceptible. Need for hospita-
lisation and mortality are increased by C. difficile infections
in IBD [EL 2; RG B]. Thus, testing for both C. difficile toxins is
recommended in every IBD patient with colonic involvement
and flare. This item was adopted into our safety-checklist.
The therapy consists of metronidazole or vancomycin. The
immunomodulation should be stopped if positive. Risk and
benefit of continued therapy should be questioned in such
patients [EL 5; RG D].5.1.6. Food hygiene
In the consensus on opportunistic infections the ECCO
recommended (statements OI 7G and H) food hygiene
(avoiding raw eggs, unpasteurized milk products and
insufficiently cooked meat) for the prevention of Salmo-
nella sp. infections in patients under immunomodulatory
therapy [EL 5, RG D] [1]. Food hygiene is also relevant
concerning travel diarrhoea (see ECCO statement OI 8 J) and
Listeria infections (see above Section 4.2 as well as ECCO
statement OI 7 J). The facultative recommendation to
instruct a patient about food hygiene before start of anti-
TNF therapy was therefore added to our safety-checklist.
5.2. Viral infections
5.2.1. Hepatitis B
Consensus Statement:
IFX therapy can lead to an exacerbation of hepatitis B
with fatal hepatic failure [EL4, RG C]. Therefore, all
patients must be screened for hepatitis B before
initiation of IFX [EL 2b, RG B]. In patients who are
HBs-Ag positive viral load should be determined and
antiviral treatment should be initiated prior to IFX [EL
4, RG C]. Serum aminotransferases and HBV viral load
should be monitored in these patients [EL 4, RG C].
Chronic hepatitis B as indicated by HBs-Ag positivity is
found in 2% of patients with Crohn's disease.145 Immunosup-
pressive therapy of any type may lead to reactivation of
chronic hepatitis B.146,147 Acute hepatic failure requiring
liver transplantation due to HBV reactivation associated with
IFX therapy has been reported.148 Acute hepatitis due to HBV
reactivation occurred between 10 days and 6 months after
IFX therapy. Prophylactic administration of lamivudine can
prevent reactivation of chronic Hepatitis B due to immuno-
suppression of other types and indications.149–151 In a Spanish
study 80 patients with Crohn's disease requiring IFX were
assessed for chronic hepatitis B which was found in 3
cases.152 Two patients with positive HBs-Ag and negative
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them died due to hepatic failure. The third patient was HBV-
DNA positive and received lamivudine 100 mg/d before
initiation of IFX therapy. No signs of acute hepatitis occurred
and HBV-DNA was cleared. In other cases no relevant
increases in AST/ALT and HBV-DNA were noted under
concomitant lamivudine therapy of 100 mg/d during anti-
TNF treatment.153,154 It was also shown that acute hepatitis
due to HBV reactivation after IFX could be controlled with
lamivudine in one RA patient and one CD patient.155,156 The
possibility of developing resistance to lamivudine has to be
kept in mind.157
5.2.2. Hepatitis C
Consensus statement:
Treatment with IFX appears to be safe in patients with
chronic hepatitis C [EL 3b RG C].
Evidence of chronic hepatitis C infection should be
sought in all patients before initiation of IFX. Patients
with concomitant HCV infection should be monitored by
determination of aminotransferases and HCV viral load
[EL 4, RG D].
Up To 6% of patients with IBD have concomitant hepatitis
C.158 The course of chronic hepatitis C under anti-TNF
treatment on a regular basis has been evaluated in 24 patients
with rheumatoid arthritis (16 retrospectively and 8 prospec-
tively, 21 under etanercept and 3 under IFX).159 HCV viral load
and liver function test were recorded at baseline and followed
up at varying times (on average every three months) after
initiation of anti-TNF treatment. Neither liver function tests
nor viral load changed significantly during follow up. Another
study followed 31 RA patients with concomitant HCV under
anti-TNF therapy over a median of 22 months and found a
significant increase of viral load under anti-TNF therapy in 4
patients; a closemonitoring of viral loadwas therefore recom-
mended.160 Also several other authors reported cases of
patients with either IBD or RA who had concomitant chronic
hepatitis C and received anti-TNF treatment (mainly IFX) once
or several times.153,154,161–164 Based on these reports anti-TNF
therapy appears to be relatively safe in patients with chronic
hepatitis C. However, since data are limited and the long-term
outcome has yet to be evaluated evidence of HCV infection
should be sought in patients before anti-TNF therapy and its
monitoring of aminotransferases and HCV viral load has to be
recommended.165,166
5.2.3. EBV, EBV and lymphoma
Epstein–Barr virus is associated with the occurrence of
lymphomas under immunosuppression due to solid organ
transplantation.167 Also in IBD a few cases of lymphomas in
association with EBV reactivation under conventional immu-
nosuppression168–170 as well as under IFX have been
reported.171,172 The viral load of EBV increased more than
100-fold in 8 of 21 pediatric patients with CD under
infliximab.173 Two larger studies did not confirm these data
in adult patients with CD.174,175 No significant difference in
EBV viral load between patients with CD and controls and no
significant influence of immunosuppression and IFX on theviral load was found. Mononucleosis has occasionally been
reported but not as a serious adverse event.5.2.4. Varicella-zoster, measles, rubella
Exacerbation of varicella zoster has been described in some
IBD patients after IFX infusion but whether the risk is
increased due to IFX cannot be concluded.14,176 Three cases
of severe primary varicella infections under combined
immunosuppression including IFX have been reported and
were complicated by visceral affections necessitating inten-
sive care treatment and death due to fulminant hepatic
failure.177–179 Up to now, there are no data on infections
with measles or rubella under anti-TNF therapy.5.2.5. Herpes simplex
Herpes simplex (HSV) infection during a combined immuno-
suppression including IFX has been reported.180,181 Also one
case of HSV infection after solely IFX therapy has been
reported by Colombel et al. but not as serious adverse
event.14 Whether the risk of herpes simplex reactivation is
higher under IFX as compared to other agents in IBD is
unknown. Also no data exist on how to proceed with an anti-
TNF therapy during herpes reactivation. It seems rational to
postpone the application of IFX until after cutaneous herpetic
lesions have healed and to consider antiviral therapy in
recurrent HSV reactivation under IFX. This is in agreement
with the ECCO consensus on opportunistic infections.5.2.6. Cytomegalovirus (CMV)
Although regarded as opportunistic infection CMV is men-
tioned in the section of other viral infections for clearness. In
the statement OI 4A of the ECCO consensus on opportunistic
infections screening for latent CMV infection was not
recommended (EL 2; RG B].1 Latent or subclinical CMV was
not considered a contraindication for immunomodulation [EL
2, RG B]. However, CMV colitis should be excluded (tissue
PCR, immunohistochemistry) in cases refractory to immuno-
modulatory therapy before escalating the therapy [EL 3, RG
C]. This has also to be applied to anti-TNF therapy and was
therefore adopted into the safety-checklist. In case of severe
colitis immunomodulatory therapy should be discontinued
and antiviral therapy should be initiated. In systemic CMV
infection immunomodulatory therapy must be discontinued
[EL2, RG B].5.2.7. Human immunodeficiency virus (HIV)
ECCO recommended (statement OI 3G) to consider testing
for HIV before initiation of immunomodulating therapy due
to anecdotal reports of increased risk and severity of HIV
related infections [EL 4, RG D].1 However, immunomodula-
tors were not considered as necessarily being contraindi-
cated in HIV positive patients [EL 4, RG D]. There are some
data that anti-TNF therapies have not that detrimental
effect in HIV positive patients one would assume.182
Nevertheless, the physician treating a patient with an anti-
TNF agent has to calculate the risk of therapy and has to
know if the patient is HIV positive. Therefore, this item was
adopted into the safety-checklist.
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6.1. Life vaccines
Consensus statement:
There are no data on safety and efficacy of live vaccines
in patients who receive IFX. In otherwise immunosup-
pressed individuals live vaccines including oral polio
vaccine, vaccinia, bacillus Calmette–Guerin, varicella
and live oral typhoid are contraindicated. Therefore
these vaccines should also be avoided under IFX therapy
and, if considered necessary, be given before initiation of
immunomodulatory therapy including IFX. [EL 5, RG D]Some life vaccines are absolutely contraindicated in solid-
organ transplant recipients (oral polio vaccine, vaccinia,
bacillus Calmette-Guerin, live oral typhoid).183 Oral polio
vaccine is also contraindicated in family members of
transplant recipients. If these recommendations are also
reasonable for patients under anti-TNF treatment has yet to
be evaluated. However, since an inactivated polio vaccine is
available and has proven safety and efficacy in renal
transplant recipients it should be favoured if indicated.184
Also a killed parenteral Vi polysaccharide vaccine for typhoid
fever is available instead of the live attenuated oral Ty21a,
but there are no data on its safety and efficacy under anti-
TNF therapy.185 Concerning measles vaccine two small
studies were conducted in 31 children who underwent liver
transplantation.186,187 In patients who received only one
vaccine post-transplant 41% had seroconversion and 29%
retained protective titers after 6 months, whereas these
numbers were 85% and 64%, respectively, in children who
received one dose prior to transplantation and one dose after
transplantation. Measles vaccination was considered safe in
both studies which was also concluded from data of 51 bone
marrow transplant recipients of whom half received current
immunosuppression.188 There are no data concerning mea-
sles vaccination under anti-TNF therapy.
Severe varicella infection has been reported in relation to
IFX therapy but there are no data concerning safety and
efficacy of varicella vaccine. In 17 children who underwent
kidney transplantation and who received live attenuated
varicella vaccine (Oka strain) post transplant protective
titers were achieved in 94% after one year.189 One case of
mild post vaccination varicella occurred. Some concerns
about varicella vaccination in immunosuppressed individuals
have been raised and include the possibility of reactivation
of the Oka strain, transmission of vaccine virus to the general
population and development of zoster.183 The ECCO recom-
mends VZV vaccination in every IBD patient with a negative
history for chickenpox, shingles or prior VZV vaccination
before initiation of any immunomodulatory therapy (state-
ment OI 4C).1 Passive immunisation after exposure to
varicella or herpes zoster is appropriate in non-immunised,
seronegative patients under immunosuppression including
IFX.
Rubella vaccination is rarely required in adults except for
prevention of rubella in young females. Rubella usually doesnot cause severe infection in transplant recipients, however,
to prevent congenital rubella syndrome, vaccination might
be necessary in some instances. The vaccine has shown
safety and efficacy in a combination with mumps and
measles vaccine in 31 pediatric liver transplant recipients.190
There are no data on these vaccines in patients receiving
anti-TNF therapy.6.2. Killed vaccines
Consensus statement:
Killed (inactivated) vaccines against pneumococci and
influenza are safe under IFX [EL 2b, RG B].
Both vaccinations are recommended for patients with
chronic diseases as well as immunocompromised indivi-
duals. Since the risk of infection increases with age all IBD
patients over 65 years should undergo vaccination for
influenza and pneumococci prior to IFX. Response to
some killed vaccines may be reduced under IFX therapy
and should therefore precede IFX if possible [EL 2b RG C].
Vaccination against influenza should be repeated yearly
under ongoing therapy with IFX.Safety and efficacy of the 23-valent pneumococcal
polysaccharide vaccine was evaluated in 149 patients with
RA compared to 47 healthy controls.191 Patients with RA
were either treated with anti-TNF agents without metho-
trexate (IFX n=27, etanercept n=35), anti-TNF agents with
methotrexate (IFX n=37, etanercept n=13) or methotrexate
alone (n=37). Vaccination was safe and response to
vaccination was higher in patients treated with anti-TNF
agents without concomitant methotrexate or methotrexate
alone. In another controlled study using a 7-valent pneumo-
coccal vaccine the vaccine was well tolerated but response
was altered under anti-TNF therapy; the authors concluded
that vaccination should precede anti-TNF therapy.192
Trivalent vaccination against influenza was studied in 62
RA patients who received IFX or etanercept alone, in 50 RA
patients who received IFX or etanercept in combination with
methotrexate, in 37 RA patients receiving methotrexate
alone and in 18 healthy controls.193 All groups responded
well although response was better in patients receiving
methotrexate alone as compared to both anti-TNF groups. In
a controlled study on influenza vaccination Fomin et al.
reported that although the overall response was good in RA
the percentage of responders to the Hong Kong antigen was
significantly lower as compared to healthy controls194; there
was no difference between anti-TNF agents and other
DMARDs regarding response to vaccination. In another two
trials evaluating the response to influenza vaccine under
adalimumab and infliximab, respectively response was only
modestly impaired under anti-TNF therapy.195,196 Neverthe-
less Elkayam et al. demonstrated that the response to
influenza vaccination was higher if the vaccine was applied
before IFX therapy as compared to patient receiving the
vaccine three weeks after IFX administration.197 Vaccination
was well tolerated in all mentioned trials.
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Consensus statement:
Treatment with IFX has to be avoided in patients with pre
existing demyelinating diseases such as multiple sclerosis
and optic neuritis since it may worsen the disease [EL 4,
RG C].
In case of new-onset of neurological and/or visual
symptoms IFX therapy has to be stopped and a neurologist
and/or ophthalmologist has to be consulted [EL 4, RG C].
The risk of demyelinating diseases in patients with IBD has
been investigated in several studies.198–202 Most of these
studies revealed an increased risk for MS in IBD reported to be
up to four-fold. In a retrospective study concurrent cases of IBD
andmultiple sclerosis (MS)were characterized bymild severity
of both diseases.203 Demyelinating diseases such as MS, optic
neuritis (ON), Guillain–Barré syndrome, chronic inflammatory
demyelinating polyneuropathy, and other demyelinating
neuropathies have been reported in association with TNF-α
antagonist treatment.204 MS is generally believed to be an
inflammatory immune-mediated disorder, the pathologic
hallmark of which is the demyelinated white-matter plaque
in the central nervous system.205 Tumor necrosis factor alpha
(TNF-α) is thought to be a potential mediator in this
disorder.206 However, anti-TNF-α agents for MS treatment
unexpectedly worsened the disease. Negative results were
described in two patientswith rapidly progressiveMSwho have
been treated with two IFX 10 mg/kg infusions at intervals of
two weeks in an open-label phase I trial.207 Although clinical
worsening of MS was not reported, the number of gadolinium
enhanced brain lesions on MRI increased.
The mechanism by which TNF-α antagonists improve
inflammatory diseases such as IBD and RA, but not MS is
unknown. It might be explained by the fact that IFX does not
seem to be able to cross the blood-brain barrier and neutralize
local TNF-αmediated tissue injury, since itwas not detected in
the cerebrospinal fluid after treatment. Furthermore, IFX
could enhance the activation ofmyelin-specific autoreactive T
cells, thereby exacerbating autoimmune demyelinating dis-
ease.208 In large trials in patients with IBD treated with
IFX4,139,140,209–211 4 cases of neurological complications have
been described.140,211
Three safety analyses of large series of IBD patients under
IFX revealed one patient with demyelination suggestive of
MS, who was reported in detail elsewhere,212 out of 500
patients with CD treated with IFX at the Mayo Clinic, one
patient with verified MS out of 651 IBD patients of the Danish
Crohn Colitis Database treated with IFX (followed for a total
of 2009 person-years post-treatment), and 3 cases of
confirmed demyelination in IBD patients treated with IFX in
Edinburgh covering 620 patient-years of follow-up.14,133,201
Very recently the relative reporting of IFX adverse events
to the U.S. Food and Drug Administration (FDA) was assessed
with the public release version of the adverse event
reporting system (AERS) database by using a disproportional
analysis to calculate the empiric Bayes geometric mean and
the corresponding 90% confidence intervals (EB05, EB95).213
The data revealed a relationship between IFX treatment andneuropathy (EB05=3.8). Mohan et al. described 20 cases of
demyelinating disease reported to the AERS in association
with anti-TNF therapy in patients with inflammatory
arthritides.214 Two of them had received IFX and 18 had
received etanercept. The most common neurological symp-
toms were paresthesias, visual disturbances, confusion and
gait disturbances that developed after a mean of 5 months of
therapy (range 1 week–15 months). Partial or complete
resolution of symptoms was seen in all patients after drug
discontinuation, and one patient demonstrated a positive re-
challenge with exacerbation on re-exposure to etanercept.
Optical neuritis (ON) can be caused by a variety of different
aetiologies. Acute demyelinating ON is one of the most
frequently encountered optic neuropathies and is best
known for its association with MS.215,216 In the review of
Mohan et al. ON was reported to be the second most common
presentation of demyelinating disease (8 of 20) including two
patients in whom ON was the sole presenting symptom.214 In a
very recently published review 15 additional cases of isolated
ON associated with TNF-α antagonist treatment have been
described.216 Eight of these patients had received IFX (2
patients with CD and 6 patients with RA), 5 had received
etanercept, and 2 patients had received adalimumab.217,218
All patients but one received steroids as treatment for ON.
Eleven patients experienced complete or partial resolution.
Several additional cases of MS or ON in patients with IBD while
on IFX therapy have been described in the literature.212,219–222
The evidence that the described neurological complica-
tions are associated with IFX treatment is based on the
temporal relationship between treatment and onset of
neurological symptoms, on the improvement after IFX was
stopped and, additionally, the positive re-challenge in some
cases.214,223,224 Thus, patients under IFX treatment should be
monitored for neurological symptoms. Data on other neuro-
logical adverse events are sparse. Seizures seem to be very
rare under IFX treatment without evidence of causal relation-
ship.204 Furthermore, in a large cohort of patients with
juvenile idiopathic arthritis 17 neuropsychiatric adverse
events occurred under 81 IFX treatments, including psychoses
(2), depression (2), anxiety (2), and nervousness (4).225
8. Hepatotoxicity
Consensus statement:
In patients with clinically significant liver disease IFX
therapymay be considered in selected cases [EL 5, RGD].
Treatment with IFX should be avoided or discontinued in
patients with transaminases more than three times the
upper limit of normal [EL 5, RG D]
Liver function tests should be determined prior to IFX
treatment, after induction treatment, and at least
every 4 months while on IFX maintenance treatment.
[EL 5, RG D]
Abnormal hepatic biochemistries (defined by any eleva-
tion of serum aspartate aminotransferase, alanine amino-
transferase and/or alkaline phosphatase above the upper
limit of normal) can be found in nearly one-third of IBD
patients regardless of disease activity.226 Hepatic adverse
events in patients while on IFX treatment include elevated
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and acute liver failure. However, severe hepatic adverse
events in patients with IBD are very rare. In clinical trials
hypertransaminasaemia was observed in a greater proportion
of patients receiving IFX than those receiving place-
bo.4,140,211,227–232 Usually the patients with elevated transa-
minases were asymptomatic and the increased liver function
tests decreased or normalised regardless of whether IFX was
continued or not. Elevations of alanine aminotransferase
(ALT) were observed in 44% of CD patients (placebo 38%) and
in 19% of UC patients (placebo 12%) under infliximab therapy.
Most of the elevations were mild and in only up to 2%≥5×the
upper limit of normal. Two CD patients receiving IFX in
clinical trials developed markedly elevated transaminases
and were diagnosed with acute hepatitis possibly related to
IFX.227 Data available from the TREAT-Registry suggested a
potential of IFX for liver toxicity since hepatic enzyme
abnormalities were reported in 1.05 per 100 patient-years in
IFX-exposed patients and 0.69 events per 100 patient-years in
patients not exposed to IFX.132 However, this could not be
confirmed in a recently performed assessment of the relative
reporting of IFX adverse events to the U.S. Food and Drug
Administration (FDA) (public release version of the adverse
event reporting system (AERS) database) using a dispropor-
tionality analysis213: A relationship between IFX treatment
and hepatitis was not observed.
A review of voluntary post-marketing data (576,000 patients
with over 1.3 million patient-years of exposure) identified 31
cases of severe hepatic reactions until 2004, including 5
patients with acute liver failure.227 Two of them died and 3
requiring liver transplantation. Seven of these 31 cases
occurred in CD patients, including one death and one liver
transplantation. Most of these cases are confounded by
hepatotoxic concomitant medications and serious comorbid
diseases making it difficult to establish a causal relationship
between IFX and these hepatic adverse events. Furthermore,
several hepatic adverse events under IFX treatment have been
published as case reports.233–240 These reports included 3 cases
of autoimmune hepatitis in patients with chronic arthritis/
spondylitis with resolution of transaminases under steroid
treatment.233,237,239 Two case reports described cholestatic
liver injury in women with CD and UC, respectively, after a
single infusion of IFX.234,235 Other case reports run from courses
of acute hepatitis (including one patient with Crohn's disease)
with complete normalization of liver tests238,240 to cases of
severe liver dysfunction.236,237 These included a 39-year-old
female patient with RA who developed severe cholestatic liver
disease with hepatic failure necessitating liver transplantation.
She was on IFX treatment for 8 months and had no history of
hepatic disease and exposure to hepatotoxic drugs.237
The reason for liver toxicity associated with IFX is
unknown. However, it did not re-occur in 3 patients who
were subsequently treated with etanercept.236,240,241 It is
noteworthy that preexisting liver disease and/or concomi-
tant medication with potentially hepatotoxic drugs may
increase the risk of hepatic adverse events of IFX. Until now,
available data could not clearly ascertain this hypothesis,
especially if liver cirrhosis is a significant predictor for
hepatic adverse events under IFX treatment. In patients with
primary sclerosing cholangitis IFX seems to be safe, but not
effective. While a report of 2 patients described an
improvement of liver function tests after IFX treatment,242a small double-blind, placebo-controlled, randomized study
failed to demonstrate efficacy of IFX.243 The risk of IFX
treatment in patients with chronic hepatitis B and C is
discussed elsewhere in this consensus.
9. Congestive heart failure
Consensus statement:
In patients with mild congestive heart failure (NYHA
classes I and II) but a normal ejection fraction IFX
therapy may be considered after a fully informed
discussion with the patient [EL 5, RG D].
In patients with a reduced ejection fraction, especially
in case of NYHA class III and IV, IFX therapy has to be
avoided [EL 1b, RG A].
In patients who develop new onset or worsening of
congestive heart failure IFX therapy has to be stopped
and a cardiologist has to be consulted [EL 4, RG C].
The estimate for the co-morbidity of CHF and inflamma-
tory bowel disease is likely to be low. A recently published
meta-analysis revealed no evidence of an increased cardio-
vascular-disease-specific standardized mortality ratio for CD
as well as for UC.244 New onset and worsening of congestive
heart failure (CHF) has been described in association with
anti-TNF-α treatment.204 This cognitionwas astonishing since
TNF-α inhibition has previously been thought to be a
promising treatment in patients with CHF. First preclinical
and open pilot studies with etanercept in CHF showed an
improvement of the left ventricular ejection fraction and in
the 6-min walking distance.245,246 However, a large, random-
ized, placebo-controlled trial evaluating etanercept in
patients with CHF could not confirm this described thera-
peutic effect and ruled out a clinically relevant benefit of
etanercept on the rate of death or hospitalization due to
CHF.247 In the American arm of the trial (RENAISSANCE trial) a
trend towards higher mortality in etanercept treated
patients was even noted. Very similar results were produced
by a phase II, randomized, double-blind, placebo-controlled
pilot study named ATTACH (Anti-TNF alpha Therapy Against
Chronic Heart Failure).248 This trial evaluated the efficacy
and safety of IFX in patients with NYHA class III and IV and a
left ventricular ejection fraction≤35% representing patients
with severe disease. One hundred fifty patients were
randomly assigned to receive placebo, IFX 5 mg/kg or IFX
10 mg/kg at 0, 2, and 6 weeks. The combined risk of death
from any cause or hospitalisation for heart failure through
28 weeks was increased in the patients randomized to 10 mg/
kg IFX (hazard ratio 2.84; P=0.043). All-cause mortality at
1 year showed that 4 patients (8.2%) in the placebo group died
compared with 4 patients (8%) in the IFX 5 mg/kg group and
8 patients (15.7%) in the IFX 10 mg/kg group. Thus, the
conclusion was that short-term treatment with IFX did not
improve and high doses (10 mg/kg) adversely affected the
clinical condition of patients with moderate-to-severe CHF.
IFX has not been studied in patients with mild heart failure
(NYHA class I and II). In several large studies investigating the
efficacy and safety of IFX in IBD only a single patient with
heart failure was reported who died from multisystem organ
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amyloidosis.211
In the post-marketing period of IFX rare cases of new-onset
or worsening of CHF have been described. In an analysis of data
from the U.S. Food and Drug Administration's (FDA) Med Watch
program 47 patients who developed new onset (n=38) or
worsening (n=9) of CHF during treatment with etanercept
(n=29) or IFX (n=18)were reported.249 Half of the patientswith
new-onset of CHF had no identifiable risk factors. The median
time interval from the first dose of TNF-α antagonist to new-
onset or exacerbation of CHFwas about 4 months (range 24 h to
24 months). Ten of the 38 patients who developed new-onset
CHF were under the age of 50 years, six of them had received
IFX and 4 had received etanercept. After TNF-α inhibitor
therapy was discontinued and heart failure therapy was started
in these 10 patients, 9 had complete or partial resolution of CHF
and one patient died. Six of the patients with new-onset CHF
had CD, and in 3 of them no risk factor could be identified. In a
review of the safety data of anti-TNF-α agents obtained from
the FDA Freedom of Information Database 132 cases of heart
failure were reported in the postmarketing period from 1998 to
March 31, 2002.250 This corresponded to 0.6/1000 patients.
Very recently the relative reporting of IFX adverse events to the
FDAwas assessed with the public release version of the adverse
event reporting system (AERS) database by using a dispropor-
tionality analysis.213 A relationship between IFX and CHF could
not be established. Thus, CHF is a rare adverse advent under
anti TNF-α treatment. Several trials revealed similar rates of
CHF under and without anti TNF-α treatment in patients with
CD and RA.251–255 Two safety analyses of large series of IBD
patients under IFX revealed only one patient with worsening of
heart failure out of 500 patients with CD treatedwith IFX at the
Mayo Clinic and no case of CHF in IBD patients treated with IFX
in Edinburgh covering 620 patient-years of follow-up.14,133
Reports suggested that IFX may be associated with life-
threatening tachyarrhythmias and bradyarrhythmias. A single-
blind, placebo-controlled cross over study of 75 patients with
chronic arthritis revealed a non-significant trend of more new-
onset cardiac arrhythmias, particularly ventricular tachyar-
rhythmias, developed during IFX infusion.25510. Haematological side effects
Consensus statement:
In case of relevant haematological dyscrasias such as
pancytopenia, leukopenia, neutropenia, thrombocyto-
penia, and aplastic anaemia during IFX treatment, IFX
should be discontinued if no other reason has been
identified [EL 5, RG D].
Blood count should be examined prior to start of IFX
treatment, after induction treatment, and at least
every 4 months while on IFX maintenance treatment [EL
5, RG D].
Different haematological dyscrasias such as pancytopenia,
leukopenia, neutropenia, lymphopenia, thrombocytopenia,
and aplastic anaemia have rarely been reported in association
with IFX administration, some with fatal outcome. Consideringclinical trials, performed primarily in adult patients with IBD,
rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis
and plaque psoriasis data of safety of IFX in 5706 IFX-treated
patients and1600 placebo-treatedpatients are available.256,257
The overall incidence of hematologic abnormalities was low:
anaemia 2.6% (IFX-treated) vs. 2.8% (placebo-treated); leuko-
penia 1.5% vs. 0.9%; neutropenia 1.1% vs. 0.4%; pancytopenia
0.0% vs. 0.1%; thrombocytopenia 0.5% vs. 0.2%. Some of these
hematologic adverse events have been reported more com-
monly in paediatric CD patients, such as leukopenia (9%) and
neutropenia (7%).258,259 Further haematologic adverse events
are reported primarily from post-marketing surveillance data
from the FDA250 or have been published as case reports. Several
cases of pancytopenia,260–263 leukopenia, and neutrope-
nia250,264–266 under IFX treatment administereddue to different
indications have been published. Some of them have been
associatedwith requirement of blood transfusions and G-CSF or
severe infections including fatal outcome. It is noteworthy,
that in many of these cases a concomitant treatment with
azathioprine, methotrexate or leflunomide was administered.
Also thrombocytopenia has rarely been observed in patients
while on IFX therapy and reported to the FDA.250 Several
additional cases havebeenpublished267–271 including a 15-year-
old male patient with Crohn's colitis who developed thrombo-
cytopenia 6 days after the first IFX infusion and was diagnosed
to have idiopathic thrombocytopenic purpura.267 Thedescribed
haematological side effects of IFX are not specific and have also
been reported in association with other anti-TNF-α inhibitors
such as etanercept and adalimumab.250,272–277
Concomitant medications make it difficult in some cases
to ascertain causality between haematological abnormalities
and IFX. However, three cases of rechallenge of anti-TNF-α
inhibitors have been published which are strong arguments of
causality between haematological abnormalities and anti-
TNF-α antagonist.266,271,27311. Intestinal strictures, stenosis, or bowel
obstruction (SSO)
Consensus statement:
IFX does not seem to increase the risk for the
development of intestinal strictures, stenosis, or
bowel obstruction (SSO) [EL 2b, RG B].
Patients with pre-existing SSO are less likely to respond
to IFX treatment [EL 4, RG C].
Intestinal strictures, stenosis, or bowel obstruction (SSO)
are common complications of CD. During the early stages of
CD, inflammation may result in intermittent obstructive
manifestations due to bowel wall edema and accumulation
of inflammatory cells in the mucosa. Persistent inflammation
induces thickening of the bowel wall with enhanced collagen
production and subsequent fibrostenotic narrowing and
stricture formation.278,279 Thus, bowel obstruction may
primarily result from florid inflammation or from irreversible
fibrostenosis or from a combination of both. While the
inflammatory component is likely to respond to anti-inflam-
matory drugs, this is not the case in fibrotic changes.280,281 The
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due to IFX is somewhat conflicting. In randomized controlled
trials aswell as in two retrospective studies some patientswith
newly developed bowel obstructions under IFX treatment have
been described, especially at the site of earlier severe
ulcerations.139,282–284 Furthermore, in an open-label trial
including patients with active CD the ulcerative lesions
markedly improved after giving IFX, but the intestinal
diameter evaluated by colonoscopy tended to narrow.285 In
an analysis of the post-marketing experience of adverse events
of IFX a signal for bowel obstruction was found specific for CD,
which might be due to confounding by indication.213 On the
other side data from the ACCENT I trial revealed that the
incidence of new presentation of intestinal SSO during the
study period was lower in patients on IFX maintenance
treatment than in the placebo maintenance group suggesting
that the use of IFX does not lead to an increase in the
development of intestinal SSO.4,286 Data from the TREAT
registry, a prospective, observational, multicenter registry in
North American patients with CD, confirmed these results.287
Multivariate analysis revealed that severity and duration of
disease, ileal location, and new corticosteroid use were
predictors of intestinal SSO but neither previous nor new use
of IFX. Thus, considering all available data IFX does not
seem to increase the risk for the development of SSO. Data of
open-label and retrospective studies revealed that patients
with SSO have an increased risk of not responding to IFX
treatment.288–291 This poorer response was especially found in
patients with bowel dilation proximal to the strictures.288 An
open-label trial evaluating the safety and efficacy of IFX in
patients with symptomatic SSO refractory to steroids and/or
immunosuppressive agents was discontinued prematurely due
to safety thresholds of more than two surgeries within the first
5 patients.289 However, the indications for surgery were
primarily due to additional perforating disease. Very recently
data from Japanese nationwide surveys confirmed that
stricturing behavior was a risk factor for ineffectiveness of
IFX.292 In contrast to these data successful IFX treatment of
inflammatory stenosis in CD has been reported in case reports
as well as in retrospective analyses and prospective investiga-
tions suggesting that a subgroup of patients may respond
to anti-TNF-α therapy, especially those with florid inflamma-
tion and no or minor fibrosis.293–297 Thus, under consideration
of available data and the difficulty to distinguish between
inflammatory and fibrotic obstruction IFX should only be used
cautiously in patients with documented SSO and cannot be
recommended in this situations in general.
12. Concomitant medication
Consensus statement:
During therapy with IFX concomitant medication with
steroids, AZA/6-MP, and MTX should be restricted to the
minimum required for clinical effectiveness [EL5, RG D].
Combination of IFX with other types of immunosuppres-
sant and immunomodulators, including cyclosporine,
tacrolimus, mycophenolate mofetil, as well as ana-
kinra, etanercept, and other anti-TNF agents, is not
recommended [EL5, RG D].Concomitant medication allowed in the large studies of
infliximab included 5-ASA, steroids, AZA/6-MP and
MTX.4,298,299 Toxicity data did not reveal additional risk
due to any specific combination of infliximab with any of
these drugs in RCTs, which is in accordance with post-
marketing data. Several reports suggested that addition of
an immunomodulator (AZA/6-MP or MTX) might decrease the
likelihood of occurrence of anti-infliximab antibodies, which
might be related to a decreased incidence of infusion
reactions.3 Additionally, some reports suggested that addi-
tion of an immunomodulator might prolong the duration of
remission/response during infliximab treatment by virtue of
decreased antibodies to IFX.3 However, several more recent
reports including data from the large ACT1/2 studies did not
support this view.211 Therefore, addition of an immunomod-
ulator is not a prerequisite in IFX treated patients. IFX
administration on a fixed schedule rather than on-demand
treatment might be equally effective in this regard.3,4,300,301
However, concerning safety issues other than infusion
reactions, mainly infections, ECCO concluded in its consen-
sus on opportunistic infections that the combination of
immunomodulator therapies poses a risk for opportunistic
infections [EL 3b, RG C].1 It is obvious that multi-modal
immunosuppressive treatment increases the likelihood of
infectious complications, in some analogy to the situation in
organ transplantation. This notion was recently supported by
data from a large cohort study including 22,310 patients with
CD and 111,550 controls which revealed that the combina-
tion of anti-TNF therapy with immunosuppression was
associated with 1,7-fold increased risk of sepsis.302 This
risk was even increased by 2,4-fold with the addition of
steroids. Therefore, this combination should be avoided on
the long-term whenever possible. This view might be further
supported by the occurrence of several cases of hepatos-
plenic T cell lymphomas in adolescent patients treated with
both, IFX and AZA/6-MP,303 which is discussed elsewhere in
this paper in more detail. Triple immunosuppressive treat-
ment with steroids, AZA/6-MP and IFX should be restricted to
the minimum time required, and should be administered
under vigilant surveillance for infectious complications.
Steroids should be tapered as quickly as possible in this
situation. This is particularly relevant as TREAT registry data
indicate significantly increased risk for serious infections and
mortality in steroid-treated patients.132 Immunosuppressive
drugs used in transplant medicine, like cyclosporine,
tacrolimus and mycophenolate mofetil, have not been
formally tested along with IFX in IBD patients. Their use
can therefore not been recommended along with IFX.
13. Malignancy and lymphoma
13.1. Malignancy and lymphoma in IBD
Consensus statement:
There is an increased risk for malignancy of colon and
liver in IBD [EL 2b; RG B].
There may be only a borderline risk for lymphoma in IBD
[EL 2a, RG C] and this risk is probably higher in severe
IBD [EL 5, RG D].
237The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseAn increased risk for colonic cancer has been known for
UC patients for a long time and is summarized in a
corresponding meta-analysis.304 A similar risk was discovered
in CD.305,306 A large Canadian population matched study
found an increased risk for cancer in IBD patients307; there
was an increased risk for colon carcinoma for patients with
UC (incidence risk ratio 2.8; 95%CI: 1.9–4.0) as well as for CD
(IRR 2.6; 95%CI 1.7–4.1). There was an increased IRR of
rectal carcinoma only in patients with UC (1.90; 95% CI,
1.05–3.43) and an increased IRR of carcinoma of the small
intestine only in CD patients (17.4; 95% CI, 4.16–72.9). An
increased IRR of extraintestinal tumors was observed for the
liver and biliary tract in both CD patients (5.22; 95% CI, 0.96–
28.5) and UC patients (3.96; 95% CI, 1.05–14.9).
Mostly lymphoma arise in areas involved in IBD and
symptoms of lymphoma may mimic symptoms of underlying
IBD. Earlier studies especially from tertiary centers tended
to have more positive results than recent studies which are
population based.308 There are two systematic reviews308,309
on lymphoma in IBD with conflicting results (cohort studies):
The RR differed between 0 and 10 in different studies. Most
population- and also hospital-based studies failed to identify
an increased risk for lymphoma in IBD. Only two studies from
tertiary centers (Mt. Sinai and Chicago University) showed an
increased risk possibly due to referral bias and ascertainment
bias. Summarizing some of the bigger studies an absolute risk
of 0.03%/person year was calculated. In contrast to IBD there
is a clearly increased risk (SIR 1.8; 95% CI , 1.5–3.2) of
lymphoma in patients with rheumatoid arthritis,310,311
especially in patients with high inflammatory activity.312
13.2. Immunosuppression andmalignancy/lymphoma
Consensus statement:
There is no increased risk for non-hematopoietic
malignancy in IBD patients treated with immunosup-
pressives [EL 2a, RGB].
A slightly increased risk for lymphoma cannot be
excluded for patients with IBD on immunosuppressives
[EL2a, RG C].
During the last 15 years immunosuppressives have become
the gold standard especially in severe cases with IBD and as
long-term maintenance treatment for more than one year.
There were concerns about the possible risk of malignancy
under these conditions. One extensive review found no
increased risk of non-hematopoietic malignoma in immuno-
suppressively treated patients with IBD in larger population
based studies.313 There aremultiple cohort studies on patients
with IBD and immunosuppressives with contradictory results
with respect to the risk of lymphoma. Most of the studies were
carried out in IBD-patients on thiopurines (azathioprine,
6-mercaptopurine). Their risk seems to be lower than in
patients with RA311 or post-transplant patients.314 A recent
interim analysis of the CESAME cohort suggest an overall
increased risk of non-Hodgkin lymphoma in IBD (SIR=1.89; 95%
CI 1.08–2.97, P=0.03) compared with the general population.
The excess risk appears to be related to thiopurines since ¾ of
the incident cases of non-Hodgkin lymphoma occurred inpatients receiving azathioprine.315 A meta-analysis found the
risk of IBD patients on immunosuppression to be 4 times higher
(CI 2–7.5) compared with the general population.316 Another
meta-analysis of population based studies could not find any
increased risk for lymphoma comparing patients with IBD, CD
or UC, on immunosuppressives with the corresponding group
without immunosuppressives.313 A higher risk possibly due to
severity of disease cannot be differentiated from an adverse
effect of immunosuppressives.
13.3. IFX and malignancy/lymphoma
Consensus statement:
In general, there is no evidence for an increased risk for
malignancy in IBD associated with IFX [EL 2b, RG B] and
no significantly increased risk for lymphoma up to now
[EL 2b; RB B].
Elderly smokers with COPD and IBD might have an
increased risk for lung cancer under IFX treatment [EL4,
RG D].
An increased risk for malignancy in IBD patients treated
with IFX could not be identified neither in cohort studies23
nor in a matched pair study.317 In the follow-up also no
increased risk was observed (2.9% vs. 3% malignoma in each
group for the whole 8 years).318 Also the analysis of the
TREAT data with more than 15,000 patient-years did not
reveal any significant increase of malignancy.132 In a recent
single-center retrospective cohort study with a control group
without IFX (n=743) patients under IFX with malignancy were
younger, with a median age of 42 years vs. 55 years in non-
IFX treated controls with cancer (P=0.01).23
There is one study of infliximab in patients with COPD in
which a nonsignificant increase of malignoma was found in
IFX-treated patients vs. the placebo group.319 Although
lacking a control group another study suggests an increased
risk for lung cancer in IBD-smokers under IFX — three out of
13 smokers older than 65 years developed lung cancer under
anti-TNF treatment (2 under IFX).133 Therefore IFX should be
recommended in elderly IBD smokers only very cautiously.
Prior to FDA approval of IFX an association of lymphoma
and IFX treatment was concluded to be unlikely, but not
finally excluded (0.06 vs. 0.05/100 patient-years in IFX vs.
non-IFX treated Crohn's patients (RR=1.3; 95%CI: 0.36–
5.3).132 Since approval more patients with IFX treatment
were reported with lymphoma, but no significantly en-
hanced risk could be found. The majority of these patients
had a more severe disease than controls as shown in the
TREAT registry. As a consequence of disease severity many
patients with lymphoma under IFX also had another
concomitant immunosuppressive therapy which by itself
could increase the lymphoma risk. Nevertheless, the
mortality rate because of neoplasms was similar for IBD
patients taking IFX and those without preceding IFX
therapy.287,317 Although suspected165,320 IFX has no direct
effect on apoptosis of EBV infected B-cells.321 Even taking a
small, but insignificant rate of lymphoma into account a
simulation of two 100,000 patients' cohorts suggested a
benefit for treatment with IFX.322
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Consensus statement:
Therapy with IFX is absolutely contraindicated in
patients with active malignancy outside clinical trials
[EL 5; RG D].
Patients with a history of malignancy may only be
considered for IFX therapy if the risk of tumour recurrence
is low, with a reasonable time of complete remission from
the tumor and depending on the tumour type, response to
therapy and negative metastatic work-up [EL 5; RG D].
Since patients with a history of cancer of any origin were
usually excluded from randomised controlled trials on IFX in
immune mediated diseases there is barely evidence on the
safety of IFX in this situation. In patients with advanced
pancreatic cancer IFX plus gemcitabine was studied with
respect to amelioration of tumor cachexia in one randomised
controlled trial.323 No statistical difference was noted with
respect to cachexia nor with respect to survival. However,
since survival is usually very short in these patients and due to
the small study size a possible negative impact of IFX might
have been subject to beta error. Another randomised
controlled trial studied the combination of IFX with docetaxel
also with respect to weight gain in non small cell lung
cancer.324 This trial was closed prematurely due to worse
outcome in the IFX group with respect to fatigue. In patients
with renal cell carcinoma refractory to previous immune-
therapy two small trials suggested a possible oncological
benefit of IFX but this cannot be taken as robust evidence due
to the lack of control groups.325 Physicians are usually
reluctant to administer anti-TNF therapy in patients with a
cancer history whichmight be the reason of rare reports in this
field. Nevertheless, tumor recurrence after complete re-
sponse to tumor therapy has been described after IFX.326 In
patients requiring solid organ transplantation active neoplasm
other than skin tumors are considered absolute contraindica-
tions.327 Patients with a history of malignancy may only be
considered for transplantation if the risk of tumour recurrence
is low, with a reasonable time of complete remission,
depending on the tumour type, response to therapy and
negative metastatic work-up.328,329 This approach should also
be adopted to immunomodulation with anti-TNF agents.
13.5. Hepatosplenic T-cell lymphoma
Consensus statement:
In view of cases of hepatosplenic T cell lymphoma
occurring in young male CD patients under combination
therapy with IFX and azathioprine, the concomitant use
of IFX and thiopurines in young males should be avoided,
although no causal relationship has been established
[EL 4, RG D].
Eight young patients with IBD and treated with IFX devel-
oped a very rare, but fatal hepatosplenic lymphoma.330,331As a consequence European pediatricians decided to stop
concomitant therapy of thiopurines and IFX (personal commu-
nication) in children with IBD. Very recently 8 further patients
with IBD under IFX and hepatosplenic T-cell lymphoma (all
together up to now 16) were described. Most of the patients
with these HSTCL were male (15/16), under thiopurines (15/
16), had Crohn's disease (14/16) and were under 32 years of
age (14/16).332 No cases of this rare aggressive form of Non-
Hodgkin-lymphoma have been reported in other established
indications for IFX like rheumatoid arthritis. However, few
reports exist on HSTCL in organ transplant recipients under
immunosuppressive therapy and also CDpatients under AZA/6-
MP as single immunosuppressant. The causal relationship of
HSTCL to IFX treatment remains unclear. However, strict
adherence to indications and contraindications of IFX therapy
outside of trials in young patients is advisable. A boxedwarning
for HSTCLwas added to the revised product labelling in 2006. A
recent update of the initial report by Mackey 2007 described
additional cases of HSTCL in association with α-TNF therapy,
including 3 cases on adalimumab, 2 of which had been
switched from IFX.333 As in the original case series, the
majority of patients were male, had CD and were receiving
combined thiopurine/anti TNF-α treatment, almost all of
them died rapidly despite chemotherapy. Early discontinua-
tion of AZA/6-MP in young patients with IFX therapy for CD has
been advocated. Lacking data in the pediatric age group this
recommendation is supported in adults by the observation,
that continuation of immunosuppressives beyond 6 months
offers no clear clinical benefit over scheduled IFX monother-
apy in previous thiopurine failures.33414. Infliximab in the elderly and the young
14.1. Infliximab in pediatric/adolescent patients
Consensus statement:
IFX therapy in paediatric/adolescent patients with CD is
safe considering indications, contraindications and
precautions. Rates of infusion reactions and infections
seem similar or even less than in adults. Little data are
available in UC [EL 1b, RG A].
IFX is effective for induction and maintenance of
remission in refractory paediatric CD, either luminal or
fistulizing.335,336 IFX is registered for these indications in US
and EU and a representative placebo-controlled RCTs for
induction and maintenance IFX therapy in paediatric CD have
been published.336 In addition, relevant experience with IFX
therapy in children and adolescents is available, prospec-
tively337 and retrospectively.338–340 In addition, reduced
need for corticosteroids, a positive effect on growth, and
possible use as first-line therapy in severe paediatric CD have
been reported and discussed.341,342 Following the new
concepts of IFX therapy in rheumatoid arthritis — early
aggressive therapy to halt bone destruction and alter the
course of the disease — similar ideas are discussed343 and
studies under way in CD. Much less data are available on IFX
therapy in paediatric UC.339,344–346
239The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel diseaseThe REACH study was an open-label multicenter random-
ized trial in 112 refractory CD patients aged 6–17 years
comparing 8 and 12 weeks regimens of IFX maintenance
therapy up to 54 weeks.336 Maintenance dosing with IFX every
8 weeks was superior to every 12 weeks dosing in maintaining
response and remission. The most common serious adverse
events were related to CD, 9 out of 103 randomized patients
had infectious complications, leading to discontinuation of
IFX in 6 (5%) of them. ATIs developed in 2.9% of patients
during the observation period of 10 weeks. Infusion reactions
were observed in 17% of patients. Anaphylaxis occurred in one
randomized patient, no other serious infusion reactions or
delayed hypersensitivity-like reactionswere seen. No deaths,
malignancies, tuberculosis, neurological or autoimmune
disorders were noted. In conclusion adverse events and
serious adverse events including serious infections were
comparable among patients treated with IFX every 8 weeks
vs. patients treated every 12 weeks. Safety findings in
children were also comparable to those observed in adults.
The REACH study was criticized for being underpowered and
not really demonstrating long-term efficacy and safety.347
Recently, a long-term outcome study of IFX maintenance
therapy was performed as a multicenter cohort study in
children younger than 16 years and short disease duration,
enrolled in a registry.348 Two hundred two out of 729
children received IFX. 158 patients received IFX as mainte-
nance therapies, 29 episodic, 8 of those were switched to
maintenance. Among 128 children administered mainte-
nance IFX and followedN1 year, concomitant medication at
IFX initiation included corticosteroids (52%) and immuno-
modulators (90%). By 1, 2, and 3 years, b10% of patients
continuing on IFX maintenance were receiving corticoster-
oids (Pb0.001). Following therapy initiation, 26, 44, and
33% of patients continuing on maintenance IFX over 0–1, 1–
2, and 2–3 years, respectively, had clinically inactive
disease not requiring corticosteroids or surgery. The
likelihood of continuing maintenance IFX at 1, 2, and
3 years was 93, 78, and 67%, respectively. Among the entire
IFX-treated population of 202 children, 1 patient had
conversion of PPD skin test with a normal chest X-ray.
Nine months of antituberculous therapy was administered,
1 patient received antiviral therapy for varicella infection
with progressive rash, both patients recovered without
sequelae. One Stage II Hodgkin's disease was found
intraoperatively with ileocecal resection in a 14 year old
girl. One death due to cardiac arrhythmia associated with
long QT interval occurred in a 11 year old boy. He had
previously survived sudden death from arrhythmia before
being diagnosed with CD.
To evaluate the efficacy and safety of IFX as maintenance
therapy of severe pediatric CD, comparing scheduled vs.
episodic treatment, was the aim of a randomized multicen-
ter, open-label study by Ruemmele et al.349 Forty children
with CD and a severe flare-up despite immunomodula-
tor therapy combined with corticosteroids were included.
34/40 patients came into remission and were randomized.
At week 60, 83% of children on scheduled IFX therapy (group
A) were in remission compared to 61% with episodic
treatment (group B). Relapse occurred in 23% of children
in group A and 92% in group B. No serious adverse event, no
death, malignancy/lymphoma was observed during the
study period.In general the rate of infusion reactions in children
receiving IFX338,339,341,350 seems similar to that in adults (4–
13%). The REACH study reported infusion reactions in the two
patient groups of 17% and 18%, respectively.336 In a report on
361 IFX infusions in 75 children the number of infusion
reactions (8.5%) was in the expected range, however the
number of reactions per individual child (38.6%) was higher
than reported in adults (17–24%).350 The majority of infusion
reactions are mild and discontinuation of IFX therapy is not
necessary in most cases. Female gender and the use of
immunosuppressants for less than 4 months seem risk factors
for a reaction up to the third infusion, but not for ongoing IFX
therapy later on. In addition prolonged intervals between
infusions seem to predispose to infusion reactions. Pre-
treatment with corticosteroids and diphenhydramin with
substantially decreased infusion reactions (8% of patients,
1.5% of patients) has been reported.339 Delayed hypersensi-
tivity reactions are rare. Concerning infections, data in the
paediatric literature are scarce, severe infections seem to be
similar or even less than in adults.
The spectrum of infections — bacterial, most frequently
upper respiratory tract (around 34% in the REACH study),
fungal infections, and also listeriosis and tuberculosis— is not
different to adults. The numbers for serious infections
reported in larger series in children are 3.6%,339 5%,338 5.7%
and 8%336 and within the 4–8% rate for adults reported in
prospective and retrospective clinical trials.4,14 Data similar
to the TREAT registry do not exist for children and
adolescents up to now. For paediatric patients, few reports
on severe infections exist and discontinuation of IFX therapy
is rarely mandated. However, death of a child with severe
fistulizing and stenosing CD under IFX therapy has been
reported,351 possibly due to bacterial sepsis caused by a
hidden abscess. Similar cases have already been reported in
adult CD patients.1414.2. Hepatosplenic T-cell lymphoma in the young
See Section 13.5 in the above section about malignancies and
lymphoma.14.3. Infliximab in the elderly patient
Consensus statement:
IFX therapy in elderly patients with IBD follows the same
indications, contraindications and precautions as in
younger patients. The rate of infectious complications
under IFX therapy increases with higher age. However,
especially severe and fatal infections in elderly patients
seem to be due in part to the underlying illness and
steroid co-medication, rather than IFX [EL4, RG D].
Close monitoring for infectious complications is man-
datory in IBD patients with higher age. Lung cancer has
been observed in elderly IBD patients on IFX-treatment
and a significant smoking history [EL4, RG D].
Observations on safety of IFX in elderly patients with CD
or UC are rare, with not a single study focussing on this
240 W. Miehsler et al.question. The landmark RCTs of IFX in CD and UC did not
include elderly patients. Colombel reported the Mayo Clinic
experience in 500 patients aged 5–85 years, median age
37 years. In contrast the median age of deceased patients,
of all causes, was 67 years (range 31–85 years). No clear
relation between age and treatment complications was
drawn.14 A population based cohort study of 217 patients in
Sweden also gave the impression of a higher median age in
the patients with fatal outcome, the numbers being too
small for statistical evaluation.131 Interestingly, sub-analy-
sis of the ACCENT trials looking for abscess development in
fistulising CD under IFX maintenance therapy showed an
inverse relation with age: the odds of abscess development
were 0.24 times lower for patients older than 38 years than
for patients 38 years or younger. Looking at the TREAT
registry132 including 3179 IFX treated and 3111 otherwise
treated patients with CD, without adjusting for other risk
factors, patients who died were older (OR 1,07 for each 1-
year increase in age; Pb0.001) and had a longer duration of
disease (OR 1,06 for each 1-year increase in CD duration;
Pb0.001). In an adjusted model, age (OR 1,07; Pb0.001),
duration of CD (OR 1,03; Pb0.006) and use of prednisone
(OR 2,10; P=0,016) remained independent predictors of
death. The use of IFX was not a significant predictor of
mortality.
Some information can be drawn from rheumatoid
arthritis. However, most of these patients are under
concomitant immunosuppression with methotrexate, mak-
ing comparisons with IBD questionable. In the ATTRACT
(Anti-TNF in Rheumatoid Arthritis with Concomitant Ther-
apy) trial 72 patients older than 65 years were treated with
IFX, and there was no difference in the observed effective-
ness or safety of this drug between older and younger
patients.228 Similar results were obtained in France for
elderly patients with rheumatoid arthritis.352 The absolute
number of patients stopping IFX for adverse effects was
higher and a trend for severe infections in the older patient
group (N 70 years) seemed obvious (18.2% vs. 2.8%,
P=0,08). Several other confounding factors concerning
effectiveness and safety of IFX therapy in the elderly have
been discussed in the literature, e.g. even more pronounced
immunosuppressive effect of corticosteroids in elderly
patients leading to more frequent and more severe infec-
tions, due to the underlying illness. Strictly observing the
contraindications and close monitoring especially for infec-
tious complications is mandatory in the older age group of
IBD patients.
Recently concern has been raised for the development of
lung cancer in elderly IBD patients treated with IFX. Data
from all patients (202/207) treated with IFX in Edinburgh
from 1999 to 2007 were analyzed133 comprising 620 patient-
years of follow-up. Seven deaths (3.3%) were observed and a
total of 6 malignancies (3 haematological, 3 bronchogenic).
All three cases of lung cancer were observed in patients
N65 years of age; inversely 3 of 13 patients N 65 years (23.1%)
treated with IFX and with a significant smoking history
developed lung cancer. One of them had been switched from
IFX to adalimumab. Two cases of lung cancer had been
observed also in Colombels series of 500 patients treated at
the Mayo Clinic, both elderly smokers.14 Interestingly, in a
murine model of metastatic cancer TNF-dependent mechan-
isms appear critical in maintaining tumor dormancy.35315. Mortality
Consensus statement:
Lethal adverse events are reported in controlled trials
of IFX and in numerous other reports without a
statistical difference to control groups [EL 3, RG C].
Thus, relationship between death and IFX treatment is
unclear. Risk factors for lethal adverse events in IFX
treated IBD patients are additional immunosuppression,
especially steroids, duration of disease and higher age
[EL 2 RG B].
Infections followed by malignancies are the main causes
of all deaths associated with IFX [EL 2, RG B].Mortality is the hardest endpoint for a disease or
complication, and the worst imaginable complication or
outcome. There are at the least 13 studies dealing with
mortality in CD and 9 on UC before the introduction of
IFX.306,354–370 The observation period in these studies were
at least 3.7 years in CD (mean 10.9, 3.7–17 years) and
4 years (mean 12.9, 4–19 years) in UC. There is a trend to a
slightly elevated mortality in CD (overall SMR 1.29) but not in
UC (overall SMR 1.05). The overall death rate in IBD patients
before introduction of IFX was 8.7% with a follow-up of
10.2 years (range 3.7–13.3).
Shortly after the introduction of IFX treatment in IBD
reports of severe infections, cancer and lymphomas occurred
and concerns about safety arose. Besides severe infections
also deaths were reported. All available data on mortality
rates in IBD patients treated with IFX are summarized in
Table 1. The overall mortality rate according to published
randomized controlled studies (CD and UC) was 0.3% (2/735)
in the IFX groups vs. 0% (0/427) in the control groups. The
mean follow-up in these studies was 22 weeks (range 6–
52 weeks). Combining controlled trials and reports from
routine clinical experience (excluding case reports) the
mortality rate can be estimated with 1.1 % (99/8896) at a
mean follow-up of 16 months (see Table 1).
A recently published decision analysis based on 6 studies
with 1711 patients calculated 779 deaths in comparison to an
expected death rate of 508 in 100,000 patients.322 The
Centocor periodic safety report update of August 2006
reported 0.97 cases per 1000 patient years. This means
that approximately 1 patient will die if 33 patients are
treated for 33 years. In comparison, Lichtenstein calculated
a death rate of 0.53 per 100 patient years (0.43 in control
group), or approximately 1 death per 33 patients during a six-
year treatment period.132 A similar death rate of 0.3 per 100
patient years was reported by Fidder recently.23 These are
striking differences. In contrast, the calculated annual
mortality rate in IFX treated patients was 1.3% and 1.2% in
the study of Colombel and Ljung14,131 and did not differ from
older IBD population studies with 1.0–1.4%.306,355,364 There
was also no difference in the mortality rate (1.6 % vs. 2.4%) in
a recently published study comparing 743 infliximab patient
vs. 666 non-infliximab treated patients.23 Also a meta-
analysis of different TNF antagonist in the treatment of
Crohn's disease did not show a statistical difference in the
Table 1 Documented and reported deaths in randomised controlled trials and observational studies of IFX treated patients with IBD.
Author Deaths/patients under observation Mean age survival/death Observation time (months) Comment
IFX Controls
Targan et al. 1997 209 0/83 0/25 37/ − 3 Single dose, CD
Rutgeerts et al. 1999 210 1/37 (2.7%) 0/36 34/61 12 Maintenance, CD
Present et al. 1999 139 0/33 0/31 38/ − 4.5 Fistula, CD
Cohen et al. 2000411 0/129 37/ − 3 Single center, clin. exp., CD
Farrell et al. 2000412 0/100 41/ − 6 Single center, clin. exp., CD
Arnott et al. 2001413 0/50 34/ − 3 Multicenter, clin. Exp., CD
Ricart et al. 2001176 0/100 38/ − 10.75 Multicenter, clin. Exp., CD
Kaser 2001414 0/6 46/ − 6 (mean) Single center, clin. exp., UC
Sands 2001415 0/7 0/3 37/ − 12 Multicenter, UC
Chey 2001416 0/8 60/ − 8 Single center, clin. exp., UC
Hommes et al. 2002417 0/71 35/ − 13.5 Maintenance, CD
Vermeire et al. 2002418 0/240 36/ − 2.5 Multicenter, clin. exp., CD
Hanauer et al. 20024 3/57 (0.5%) 35/? 13.5 Maintenance, CD
Doubremelle et al. 2002419 0/69 31/ − 8 Multicenter, clin. exp.,CD
Ardizzone et al. 2002420 0/63 33/ − 2.5 Single center, clin. exp:, CD
Su 2002421 1/27 (3.7%) 40/? 24 (mean) Multicenter, clin. exp., UC
Actis 2002422 0/8 20−60/ − Up to 30 Single center, clin. exp., UC
Kinney et al. 2003300 1/122 (0.8%) 43/? 13.25 (mean) Single center, clin. exp., CD
Probert 2003423 0/41 0/40 41/ − 6 Multicenter, UC
Gornet 2003424 0/30 43/ − 40 (mean) Multicenter, clin. exp., UC
Colombel et al. 200414 10/500 (2%) 37/62 17 Single center, safety update, CD
Wenzl et al. 2004425 4/153 (2.6%) 37/47 29 (mean) Multicenter, CD
Sands et al. 2004140 0/306 36/ − 13.5 Fistula, CD
Ljung 2004131 6/217 (2.7%) 38/63 − MC+UC
Ochsenkuhn 2004426 0/6 0/7 31/ − 13 Single center, UC
Armuzzi 2004427 0/20 0/20 36/ − 10 (mean) Multicenter, UC
Kohn 2004428 0/13 12−62/ − 25.6 (mean) Single center, clin. exp., UC
Bermejo 2004429 0/7 46/ − 8 Single center, clin. exp., UC
Rutgeerts 2005 ACT I u.II211 1/484 (0.2%) 0/244 41/? 54 Multicenter, UC
Jarnerot 2005430 0/24 0/21 37/ − 12 Multicenter, UC
Lemann et al. 2006431 0/108 26/ − 13 Controlled trial, CD
Poupardin et al. 2006432 0/137 36/ − 15 (mean) Multicenter, clin. exp, CD
Lichtenstein et al. 2006132 29/3179 (0.9%) 26/3111 (0.8%) 42/59 21 (mean) Treat — Registry, CD
Caviglia et al. 2007433 1/50 (2%) − 68/ − 12 Single center, safety update CD+UC
Lees et al. 2007434 1/39 (2.6%) − 32/71 6.5 (median) Multicenter, clin. exp. CU
Kohn et al. 2007435 1/83 (1.2%) − 36/71 2 Multicenter clin. exp., CU
Jakobovits et al. 2007436 0/30 − 37/ − 13 (median) Single center, clin. exp., CU
Fidder et al. 200923 12/743 (1.6%) 16/666 (2.4%) − 58 (IFX, median) 144 (control, median) Single center long term safety
Caspersen et al. 2008437 13/651 (2%) 32/54 29 (median) Multicenter, CD+UC
Vries et al. 2008438 8/147 (5.4%) − 38/53 (n=6) 59 (median) Single center safety update CD+UC
Lees et al. 2009133 7/202 (3.4%) − 32/74 28.5 (median) Multicenter, safety update, CD+UC
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242 W. Miehsler et al.frequency of death between anti-TNF (0.21%) and control
groups (0.05%).129
Overall, the number of deaths is very low but fatalities
related to infliximab are described .In one study that focused
particularly on safety issues, 50% of deaths (1% of all
patients) were regarded as IFX related.131 In addition in
most case reports a close relationship to infliximab can be
found.118,133,332,371–377 Looking at the specific causes of
death, infections were the leading cause, followed by cancer
and lymphoma. Risk factors for mortality in infliximab
treated patients are corticosteroids (OR 2.1; 1.1–3.8) and
age.132 In all studies where relevant data are available, the
average age of those who died was significantly higher than
that of survivors (60 vs. 36 years). Overall deaths due to IFX
treatment are very rare but happen, and the death rate may
increase over time. Suitable precautions should be taken to
avoid fatalities.
16. Fertility, pregnancy and breast feeding
The onset of inflammatory bowel disease (IBD) mainly occurs
in young adults within their reproductive age.378 Mainte-
nance of remission of IBD as well as prompt and adequate
treatment of active disease during pregnancy represents a
major goal for both maternal health and foetal development.
16.1. Fertility
Consensus Statement:
IFX may lead to reduced semen quality by decreasing
sperm motility and affecting sperm morphology [EL 3b,
RG B].
Whether these findings result in reduced male fertility
has not been examined. IFX treatment of men prior to
planed conception does not seem to cause embryo
toxicity [EL4, RG C].
Fertility in IBD is closely dependent upon disease activity.
Active disease is associated with reduced fertility379–381 and
female patients who underwent colectomy with construction
of an ileal pouch-anal anastomosis have an increased risk for
infertility.382–384 In remission, both, female fertility and
male reproductive capacity do not seem to be diminished
when compared to the general population.385,386 Therefore,
one might speculate whether IFX treatment may restore or
preserve fertility in female patients by inducing remission
and down regulating inflammatory mediators.
A study in mice exposed to an analogous anti TNF-α
monoclonal antibody revealed no negative effects on male
reproduction.387 In men IFX treatment within 3 months prior
to conception did not result in increased birth defects or
foetal loss.388 IFX treatment in 10 men with IBD showed an
increase in semen volume and a trend towards decreased
sperm motility and morphology.389 Sperm concentration
remained unaffected, although experimental in vitro studies
demonstrated a pro-survival effect of TNF-α on germ cells
in the seminiferous tubules during spermatogenesis, which
can be blocked by IFX.390,391 Whether these semen analysisfindings may indicate impaired fertility has not been
examined. There is one recent report on 4 patients with
ankylosing spondylitis who fathered 6 healthy children during
IFX treatment which may provide some reassurance for male
patients treated with IFX.392
16.2. Pregnancy
Consensus Statement:
Data on the safety of IFX during pregnancy are still
scarce and so far no general recommendation can be
given to continue or initiate IFX treatment during
pregnancy. However, referring that to date no in-
creased risk for foetal abnormalities including immune
defects nor for perinatal complications has been
documented in association with IFX therapy, IFX
seems to be low risk in pregnancy [EL 3b, RG B].
The decision to initiate or maintain IFX treatment
during pregnancy has to be taken on the patient's
individual clinical situation. In no case abortion might
be considered due to IFX therapy.
The FDA classified IFX as pregnancy category B, which
means that there are no data in humans and there is no
evidence of teratogenicity or embryotoxicity in mice toxicity
studies using an analogous antibody. In particular, animal
reproduction studies have not been performed, because IFX
only cross-reacts with TNF-α in humans and chimpanzees.
One study on pregnant macaques that were exposed to an
anti-TNF-α monoclonal antibody (golimumab) found no
effect on T and B cell populations in blood and lymphoid
tissues and did not indicate an impaired immune response to
antigen challenge in the offspring.393 Human experience in
using IFX during pregnancy is still limited since no controlled
studies can be conducted in this sensitive issue. Several case
reports and abstracts referring to the safety of anti-TNF
medications in pregnancy found no evidence of an increased
risk for abortion, congenital malformations or perinatal
complications in patients with rheumatoid arthritis or
CD.394–398 Only one case report can be cited that indicates
an adverse foetal outcome due to intracerebral and intra-
pulmonary hemorrhage associated with IFX infusions in a
woman who had concomitantly received mesalamine, met-
ronidazole, azathioprine, steroids and methadone.399 How-
ever, the death of this neonate was more likely attributed to
active refractory CD, but not to medical therapy.400 Small
series of women who gave birth to a child after having been
exposed to IFX during pregnancy indicated well tolerability
and no increased risk for foetal harm. Live births were
reported in more than 65%, whereas miscarriage occurred in
less than 15% of women.388 These outcomes were similar
when compared to non exposed CD patients or to the general
pregnant population in the USA. Intentional IFX treatment of
active CD during pregnancy in 10 women resulted in 10 live
births.401 In this study a total of 8 women received repeated
IFX infusions for maintenance of remission during pregnancy.
Except for two cases with neonatal illnesses, one with
neonatal jaundice and the other with respiratory distress
and a gastric ulcer, who did well at a 6-month follow-up,
Obligatory Yes No
1. Patient instructed to seek medical care
when clinical signs of infection occur
(fever, dyspnoea, neurological
symptoms…)
□ □
2. No clinical signs of active infection
(including Varicella, Herpes, Influenza,
parasites, fungal infections)
□ □
3. Screening for latent TB accomplished and
negative (obligatory: Chest X-ray, TST,
History for TB and epidemiologic risk
factors; optional: interferon γ release
assay)
□ □
→ 3.b
3.b in case of latent TB chemoprophylaxis
initiated before IFX?
□ □
4. Blood count □ □
5. Transaminases≤3× upper limit of normal □ □
6. HBs-Antigen negative □ □
→ 6 b,c
6.b HBs-Antigen positive, viral load
determined?
□ □
6.c HBs-Antigen positiv, antiviral therapy
started?
□ □
7. HIV negative □ □
8. CMV-colitis excluded (if refractory despite
immunomodulation)
□ □
9. Stool negative for C. difficile □ □
10. Informed about the risk of live vaccines □ □
11. In perianal disease: perianal abscess
excluded by imaging procedure or, if
□ □
. Checklist before start of therapy
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retardation, or infants small for gestational age. So far, the
increased rates of preterm delivery and lower birth weight in
patients with IBD seem to be associated with the underlying
disease (IBD or rheumatoid arthritis) but not with anti-TNF
treatment. A review of the FDA database on the safety of
tumour necrosis factor antagonists during pregnancy
revealed a total of 61 congenital anomalies in 41 children
exposed to etanercept (n=22) or IFX (n=19) due to
rheumatoid diseases of the mothers. Twenty-four (59%)
children had one or more congenital anomalies that were
part of vertebral abnormalities, anal atresia, cardiac defect,
tracheoesophageal, renal and limp abnormalities (VACTERL)
association. Because these malformations occurred at a rate
higher than expected, a causative effect of anti-TNF-α
treatment could not be excluded.402 However, large regis-
tries with longer follow-up periods are urgently warranted
before firm conclusions about the safety of anti TNF-α
therapy during conception and pregnancy can be drawn.
Theoretically, the chimeric structure of the IFX molecule
containing a human immunoglobulin G1 constant region
represents a large antibody, which allows little transfer of
the molecule during the first trimester. However, during the
second and third trimester IgG subclasses readily pass across
the placenta into the foetus.403 A case report by Vasiliauskas
et al. clearly indicated that IFX crosses the placenta and
revealed high IFX levels in an infant whose mother received
five 10 mg/kg IFX infusions at 6- to 8 intervals until 2 weeks
before delivery.404 Although at 6 months post partum low IFX
levels could still be detected in the infant's serum, regular T
and B cell development, normal immunoglobulin concentra-
tions as well as an appropriate response to vaccination could
be shown. Further development and health within the first
year of life remained unremarkable. Nevertheless, since
there are no case reports or studies that provide data on long
term follow-up of children exposed to IFX, a possible anti-IFX
antibody formation and/or negative effect on the developing
immune system cannot be safely excluded.
A practical approach in this difficult situation might be to
continue with IFX infusions every 8 weeks during the first
25 weeks of pregnancy and then to discontinue treatment in
order to avoid IFX transfusion to the foetus.404–406 During the
third trimester steroids may be used to control disease
activity until delivery. Thereafter, the decision to restart IFX
should be taken on an individual basis considering disease
activity and the presence of perianal fistulas.
16.3. Breast feeding
Consensus statement:
Due to the lack of adequate data nursing cannot be
generally recommended during IFX therapy, although
the few case reports published to date indicate no
toxicity [EL4, RG C].
It is not firmly known whether IFX is excreted in human
milk or absorbed systemically after ingestion. Preliminary
data have failed to detect IFX in breast milk of exposed
women with IBD as assessed by enzyme-linked immunosor-bent assay.404,407,408 The most recent study by Kane et al. on
three children breastfed by women receiving IFX during and
after pregnancy neither found IFX in the sera of the newborns
nor in the breast milk of the nursing mothers.409 In contrast,
there is one single report in abstract form that found positive
levels of IFX in the breast milk from a woman with
rheumatoid arthritis who received anti TNF-α treatment
because of a flare of the disease 4 months after delivery.410
However, all case reports of women with IBD who continued
IFX treatment while nursing their children did not indicate
toxicity.398,401,404,406–408
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Appendix A
Checklist for the safe use of Infliximab and other anti-TNF
agentsApresent, drained
(continued on next page)
Obligatory Yes No
12. No signs indicative for high-grade bowel
stenosis
□ □
13. History negative for demyelinating disease
(multiple sclerosis, optic neuritis)
□ □
14. No signs of congestive heart failure (NYHA
III–IV)
□ □
Facultative Yes No
15. Hepatitis B vaccination in a seronegative
patient accomplished
□ □
16. Screening for Hepatitis C □ □
17. Varicella vaccination accomplished if
history for chickenpox, shingles and VCV
vaccination negative
□ □
18. Pneumococcal vaccination accomplished □ □
19. Prophylaxis against Pneumcystis jiroveci
with cotrimoxacole if triple-
immunosuppression including CsA or IFX.
□ □
20. Negative history and no clinical signs for
malignancy
□ □
21. Patients instructed about food hygiene
(raw eggs, unpasteurized milk products,
uncooked meat/fish, raw vegetables)
□ □
22. Discontinuation of concomitant AZA/6-MP
especially in young male patients.
□ □
23. Dermatological evaluation if increased risk
for skin malignancy (high cumulative UV
exposure, melanoma precursors, history of
photochemotherapy, history of
immunosuppressive therapy)
□ □
A. Checklist before start of therapy (continued)
Obligatory Yes No
1. No clinical signs of active infection
(including reactivated TB)
□ □
2. Blood count and transaminases assessed
at least every 4 months (transaminases
≤3×ULT)
□ □
3. In patients with unclear symptoms
parasitic and fungal infection considered?
□ □
4. No history of infusion reactions □ □
→ 4 b
4.b Premedication administered, start at
low infusion rate
□ □
5. Neurologic symptoms, patient referred
immediately for appropriate management.
□ □
ULT: upper limit of normal.
B. Checklist during maintenance therapy
Facultative Yes No
6. Regular gynaecological evaluation □ □
7. Regular dermatological evaluation in high risk
patients
□ □
Facultative Yes No
8. Pre-travel consultation accomplished □ □
9. Stool examination for bacterial pathogens, ova
and parasites and complete blood count
(eosinophilia) in patients returning after long
term travels from developing countries
□ □
B. Checklist during maintenance therapy (continued)
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